US20120059431A1 - Intravascular Device for Neuromodulation - Google Patents
Intravascular Device for Neuromodulation Download PDFInfo
- Publication number
- US20120059431A1 US20120059431A1 US13/294,140 US201113294140A US2012059431A1 US 20120059431 A1 US20120059431 A1 US 20120059431A1 US 201113294140 A US201113294140 A US 201113294140A US 2012059431 A1 US2012059431 A1 US 2012059431A1
- Authority
- US
- United States
- Prior art keywords
- implant
- anchor
- electrode
- vena cava
- lead
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3507—Communication with implanted devices, e.g. external control
- A61M2205/3523—Communication with implanted devices, e.g. external control using telemetric means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0531—Brain cortex electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0534—Electrodes for deep brain stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N1/057—Anchoring means; Means for fixing the head inside the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36071—Pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36114—Cardiac control, e.g. by vagal stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36114—Cardiac control, e.g. by vagal stimulation
- A61N1/36117—Cardiac control, e.g. by vagal stimulation for treating hypertension
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N2001/0585—Coronary sinus electrodes
Definitions
- the present invention generally relates to implantable devices and systems, and associated methods for delivering therapy to the neurological system.
- Neuromodulation is the therapeutic alteration of activity in the central, peripheral or autonomic nervous systems, electrically and/or pharmacologically, by means of implanted devices.
- Implantable medical devices are used to deliver neuromodulation therapy to patients to treat a variety of symptoms or conditions. For example, some the implantable medical devices deliver neurostimulation therapy in the form of electrical pulses. For some conditions, electrical stimulation is performed in combination with drug therapy using implantable drug pumps that deliver drugs to the nerves undergoing neurostimulation.
- the terms “drugs” and “agent” will be used to refer to any substances to be delivered into the body for any purpose including, but not limited to, prophylactic or therapeutic purposes.
- such substances might also be biologic, such as vector-directed or mediated gene therapy, microspheres containing releasable agents, or stem cells modified to express certain proteins or other therapeutic or diagnostic compounds.
- these types of implantable devices may be long and narrow for implantation into the vascular, and in some cases can be approximately 10-60 cm in length. Such devices are preferably sufficiently flexible to move through the vasculature yet sufficiently rigid to protect the internal components.
- Certain embodiments described in the above-referenced patent applications build flexibility into the elongate implants by assembling them using a plurality of segments, with each segment defining interior space for components to be housed within it. Each segment may be separately enclosed by its own enclosure, with several such enclosures coupled together to form the implant. The enclosures are interconnected at articulations formed using silicone rubber filler or mechanical bellows.
- intravascular devices of the type described in the referenced applications may be suitable for use as neuromodulation devices to delivery electrical and/or pharmaceutical therapy to the nervous system.
- FIGS. 2A and 2B are plan views showing implantable neurostimulation components and associated implant tools.
- FIG. 3 is a plan view of an implant showing flexible interconnects between portions of the implant.
- FIG. 4A is a perspective view showing an anchor.
- FIG. 4B is a cross-section view taken along the plane designated 4 B- 4 B in FIG. 4A .
- FIG. 4C is a side elevation view of the anchor of FIG. 4A mounted on an implant device and compressed by a sheath.
- FIG. 4D schematically illustrates use of the anchor of FIG. 4C to support the implant device within the inferior vena cava.
- FIGS. 5-13 are schematic illustrations showing the heart and associated vasculature, and illustrating placement of neurostimulation devices within the body.
- the present disclosure describes intravascular systems that may be used for a variety of functions.
- the elements of the systems described below include at least one device body and typically, but optionally, at least one lead coupled to the body.
- the device body (which may include a number of body segments coupled to one another) is ideally positioned fully within the vasculature of the patient.
- Electrodes on the lead and/or on the device body itself are used to direct monopolar or bipolar electrical energy to neurological tissue or associated structures.
- These systems may additionally include one or more fluid reservoirs housing drugs or other agents to be delivered to tissue. If drug delivery in combination with electrical therapy is contemplated, the lead(s) may include fluid conduits positioned to direct drugs/agents towards the area of the nervous system that is to be stimulated.
- Combined delivery of electrical stimulation and drugs/agents might also be used to activate a drug, or to treat a tissue to create an electroporation of a cell to make it more receptive to the administered drug, or to release drugs from drug-containing microspheres having walls that burst or increase in porosity when subjected to electrical stimulation.
- neurostimulation is provided using agents (e.g. local application of neurotransmitter, neurotransmitter receptor agonists, neurotransmitter receptor antagonists, or other agents to nervous system target) with or without the use of electrical pulses.
- Electrical stimulation and/or drug delivery can also be directed to other neurological or non-neurological targets (including organs and/or associated systems) to simulate the release or inhibition of naturally produced agents such as adrenaline or insulin.
- Separate fluid delivery leads may also or alternatively be used to direct drugs/agents to an organ (e.g. kidneys, heart) or to other sites remote from the neural tissue undergoing stimulation.
- One or more anchors/retention devices may facilitate retention of the device body and/or leads or other elements within the vasculature.
- FIGS. 1A through 1C are block diagrams illustrating three exemplary intravascular neurostimulation systems.
- neurostimulation implant device 12 houses a power source 11 which may include a battery and a power generation circuit to produce operating powerstimulation.
- Device 12 also includes a pulse generator 13 for generating stimulation pulses for transmission to the patient via electrodes 25 on leads 14 or directly on the body of the implantable device 12 .
- a processor 30 may be included for controlling operation of the device 12 .
- pulse sequences may use one or all of the following parameters: amplitudes within the range of approximately 1 to 50 mAmp, pulse widths of 1 to 1000 ⁇ s, burst rates of 1 to 500 Hz, and programmable duty cycles of 1% to 100%.
- continuous electrical stimulation may be used, or pulse sequences having pulses of different parameters might be employed (e.g. for ventricular rate control in atrial fibrillation, the system might deliver pacing pulses and high-frequency neurostimulation during the atrial refractory period to prevent atrial excitation).
- the parameters may vary (e.g. ramp up or down) within a pulse sequence, or remain constant.
- Charge balancing of pulses is appropriate for preventing corrosion/electrolysis of the leads within the tissue. This is generally accomplished using wave forms having biphasic morphology or timing the capacitor recharge cycles such that there is no net imbalance of charge following stimulation.
- the system 100 may include a battery that is rechargeable.
- An external charger 32 positioned outside the patient inductively couples to a charging circuit 33 within the device 12 to recharge the battery.
- the external charger 32 includes a charging coil energizable to create an electromagnetic field that in turn induces current in a corresponding coil within the charging circuit 33 .
- the coil may be mounted to a waist pack, wearable skin-contacting/adhering patch, purse, backpack, or wheelchair cushion so that it can be carried by the patient in sufficient proximity to the charging circuit 33 .
- the coil may be positioned within a pad positionable on a patient's mattress, allowing for charging of the battery while the patient rests.
- external charger 32 might be replaced with an external inductive power supply for transcutaneously powering the pulse generator whenever stimulation therapy is to occur, thereby obviating the need for the battery.
- Energy harvesting techniques may be used by which energy generated by the body may be converted for use in charging the battery and/or operating the system.
- Piezoelectric elements mounted at various locations in the body might, for example, be used to convert motion of the heart, pulsing blood vessels, limbs, or other structures to electrical energy.
- the system 100 may also include an external programmer 34 that communicates with a telemetry interlace 36 within the implantable device 12 using radio frequency encoded signals or other telemetric methods. Telemetry systems permitting external devices to communicate with implanted medical devices are known in the art. See, for example, U.S. Pat. Nos. 6 ,824,561, 5,312,453 and 5,127,404.
- a user may use the programmer 34 to configure the device 12 (e.g. to set dosing schedules, to set the thresholds above/below which stimulation will be given, to set stimulation parameters), to review the history of therapy given by the implant, to test the implant, to allow the patient to direct release of analgesics for pain control, etc. Where multiple electrodes are employed, the programmer 34 may be used to identify the most optimal electrode pair for stimulating the target structure as discussed in greater detail below.
- Sensors 38 can be positioned for detecting certain conditions of the patient and for transmitting signals indicative of the sensed conditions. Signals corresponding to the sensed conditions may be used to trigger the delivery of therapy (see “Control Mechanisms” below) and/or sensor output may be stored within the device for subsequent retrieval using external programmer 34 .
- FIG. 1B shows a second system 10 a that differs from the system of FIG. 1A in the incorporation of a drug delivery reservoir and pump features 40 allowing administration of drugs from the reservoir to drug leads 14 a (e.g. microtubules) extending from the device.
- drug leads 14 a e.g. microtubules
- These drug delivery features may be enclosed within the same housing occupied by the other components, or the drug delivery components and neurostimulation components may be divided into two or more separate housings electronically coupled to one another.
- the FIG. 1A embodiment may be altered to provide only drug delivery, such as for neurostimulation using agents only (e.g. neurotransmitter, neurotransmitter receptor agonists, neurotransmitter receptor antagonists, analgesics), without the use of electrical stimulation.
- agents only e.g. neurotransmitter, neurotransmitter receptor agonists, neurotransmitter receptor antagonists, analgesics
- the system 100 b of FIG. 1C is similar to the system of FIG. 1B , but differs in that the neurostimulation features and drug delivery features are contained within physically separate housings.
- the drug reservoir and pump features 40 are enclosed within a container 42 having its own power source 44 as well as communication features 46 for receiving signals wirelessly transmitted by the telemetry interface 36 in the device 12 b .
- operation of the drug delivery pump can be governed wirelessly by the processor housed in the device 12 b in a master-slave type configuration.
- the arrangement of components might be reversed such that the device 12 b includes the slave components remotely controlled by a processor within the container 42 .
- device 12 houses components known in the art to be necessary to carry out the system functions.
- device 12 may include one or more pulse generators, including associated batteries, capacitors, microprocessors. and/or circuitry for generating electrical stimulation pulses and/or drug reservoirs and associated pumps associated with drug delivery.
- the '431 publication provides examples of features drug reservoirs, pumps or other drug delivery mechanisms, and other features that may be included in a neuromodulation device having drug delivery capabilities.
- device 12 may include sensors and detection circuitry for detecting the onset of neurological episodes (e.g. seizures) or other conditions within the body, and/or it may be equipped to directly or wirelessly receive feedback signals from sensors positioned elsewhere inside or outside the body. The specific sensors and other components to be provided in the device will depend upon the application for the device.
- the device 12 is proportioned to be passed into the vasculature and to be retained within the patient's vasculature.
- Suitable sites for the device 12 may include, but are not limited to, the venous system using access through the right or left femoral vein or the subclavian or brachiocephalic veins, or the arterial system using access through one of the femoral arteries.
- Specific vessels within which the device can be retained include the superior vena cava, inferior vena cava, jugular vein, subclavian vein, axillary vein, and the iliac vein, amongst others.
- the device may utilize a single- or multiple-compartment housing having a length in the range of 1-100 cm.
- a proximal portion of the device includes a connector 25 for receiving the distal end of positioning mandrel 18 , which may be used to steer the device 12 (by pushing, pulling and/or torquing) through the patient's vasculature to a target location as described in detail in the above-referenced applications.
- the connector 25 may take the form of a threaded bore for receiving a threaded screw member at the distal end of the mandrel 18 , or it may have any other type of configuration for detachably engaging the distal end of the mandrel.
- Mandrel 18 can also function as an explant tool used to engage the device 12 and withdraw it from the body.
- Mandrel 18 may serve purely mechanical purposes, or it may also be a “smart mandrel” that provides electrical and/or fluid connections. Such connections can be used to couple the device (via an instrument cable) for electrical, electronic, and/or fluid communication between the device and instrumentation located outside the body. This communication may be used for several purposes, including device testing, initiation and/or programming during implantation, and/or recharging of the device battery. If the device is to be used for drug delivery, the mandrel may be used for re-filling a reservoir in the device with drugs/agents that may be deliverable by the device to a patient.
- Including a number of separate electrodes e.g. a longitudinal array of electrodes, which may number from 2-16 or more, or a two- or three-dimensional electrode grid such as a 4 ⁇ 4 grid) per lead can provide a number of advantages.
- the system can electronically change which of electrodes in the array serves as the anode and which serves as the cathode, such that the effective site of stimulation can be moved without physical repositioning of the lead.
- the precise location of a neurological target may not always be known. With this capability, the system can sample various electrode pairs to evaluate which combination of electrodes will yield the most optimal response to stimulus.
- Electrodes examples include surface electrodes or tip electrodes.
- electrodes that engage the walls of the surrounding vessel might be used.
- an electrode may be an expandable electrode similar in structure to the anchor 16 , or the anchor 16 may be provided with multiple electrodes formed on or mounted to it.
- This type of embodiment might take the form of a polymeric stent-like grid with an array electrodes, each insulated from the other, throughout the grid structure. This arrangement allows stimulation to be delivered over a greater surface area (e.g. around the inner surface of a vessel wall) and might be particularly useful where the general location of the neurological tissue is known but the precise location is difficult to determine.
- the leads may include tip electrodes having penetrating elements that engage the vessel wall.
- Electrical stimulation leads 14 may be conventional neurostimulation leads, although alternative lead configurations may be desirable if warranted by the desired placement of the device 12 and lead within the body. Leads of the type used for defibrillation and/or pacing may be more suitable for some applications given their suitability for use in the vasculature.
- the physician will preferably want to select a location for the device 12 within a chosen vessel (e.g. the inferior or superior vena cava or aorta) that will prevent the device from blocking significant peripheral vessels extending from that vessel.
- each of the leads may include a guidewire lumen to aid in implantation of the lead.
- the system may include guidewires 21 for use in implanting the leads.
- two or more leads may be used.
- Devices for these applications may include both superior and inferior leads, multiple leads extending from the inferior and/or superior end, and/or leads extending laterally from the device body.
- Using separate neurostimulation and drug delivery implants as discussed in connection with FIG. 1C gives the user flexibility to deliver different forms of therapy to different regions of the body.
- a system might include a neurostimulation device be positioned on the venous side of the cardiovascular system and a drug delivery system positioned within the arterial system.
- FIG. 2 shows one example of a flexible device body 12 c which employs one or more rigid enclosures 50 , or “containers,” used to contain electronic components to be implanted inside the vasculature of a patient.
- the containers 50 house components known in the art to be necessary to carry out the system functions.
- the containers within an implant device can collectively include one or more pulse generators, including associated batteries, capacitors, microprocessors, and/or circuitry for generating electrical pulses for neurostimulation, and or fluid reservoirs and associated pumps for drug delivery.
- the applications referred above provide additional information of these types of components, as well as suitable arrangements of these components within the device body.
- anchor 16 includes structural features that allow the anchor to radially engage a vessel wall.
- a band, sleeve, mesh or other framework formed of one or more shape memory (e.g. nickel titanium alloy, nitinol, thermally activated shape-memory material, or shape memory polymer) elements or stainless steel, Elgiloy, or MP35N elements may be used.
- the anchor may include anti-proliferative and anti-thrombogenic coatings, although in this embodiment the anchor structure 16 or adapted to promote tissue ingrowth to as to enhance anchor stability within the vessel.
- the anchor may also have drug delivery capability via a coating matrix impregnated with one or more pharmaceutical agents.
- FIG. 4B shows one anchor 16 attached to a device 12 , although naturally one, two or more such anchors may alternatively be used.
- anchor 16 is attached to the implant 12 by a c-shaped collar 54 , or other suitable connection.
- the implant 12 may include a recessed portion 56 that allows the exterior of the anchor to sit flush with the exterior of the implant 12 when the anchor is its compressed position.
- the recessed portion should have smooth contours in order to discourage thrombus formation on the device.
- a retractable sheath 17 may be slidably positioned over the anchor 16 and implant so as to retain the anchor in its compressed position. Retraction of the sheath as indicated in FIG. 4D allows the anchor 16 to expand into contact with the surrounding walls of the vessel, thereby holding the medical implant in the desired location. Once deployed, the anchor 16 is preferably intimate to the vessel wall, which is distended slightly, allowing the vessel lumen to remain approximately continuous despite the presence of the anchor and thus minimizing turbulence or flow obstruction.
- the device 12 delivers stimulation according to a control mechanism appropriate to the particular application for the device.
- control mechanisms include but are not limited to the following: (a) open loop control, in which asynchronous stimulation is delivered without reference to sensor feedback (e.g. stimulation for pain control): (b) triggered control, in which no stimulation is delivered until a certain condition is detected and then asynchronous stimulation is initiated for a prespecified duration (e.g. stimulation to end an epileptic seizure), and (c) closed loop control, in which one or more feedback variables are actively monitored, and in which stimulator output is modified based on this feedback (e.g. stimulation for control of hypertension by balancing the reduction in heart rate vs elevation of blood pressure).
- a single system e.g. any of the systems of FIGS. 1A-1C
- closed loop control might be used for neurostimulation while open loop control is used for dnig delivery.
- the sensing capabilities of the device will be tailored to the specific application(s) for use. Possible sensing capabilities for inclusion in the device include electrical sensing of physiologic parameters (e.g. heart rate, neurological activity), biochemical sensors for indicators of a given condition, chemical sensing of changes in hormone secretion, ionic balances (e.g. changes in sodium concentrations), or sensing of physical conditions (e.g. blood pressure, physical activity, volume over load, etc).
- physiologic parameters e.g. heart rate, neurological activity
- biochemical sensors for indicators of a given condition e.g. blood pressure, physical activity, volume over load, etc.
- ionic balances e.g. changes in sodium concentrations
- sensing of physical conditions e.g. blood pressure, physical activity, volume over load, etc.
- patient conditions will be broadly used to refer to any type of state or condition that may be detected using a sensor, including but not limited to the sensors and states/conditions expressly identified herein.
- Some applications for the system 10 involve positioning the electrodes at a location in a vessel such that stimulation pulses will conduct from the electrodes through the walls of the vessel to a target nerve located outside the vessel.
- the system 10 may be provided with detection features allowing determination of the point at which the nerve and the vessel cross one another, so that electrodes nearest the crossing point may be activated for stimulation.
- detection features might include use of electrodes to monitor electrical pukes from the nerve, or to deliver mild stimulation during implantation so that specific feedback or patient reaction can be detected when the electrode is close to the nerve.
- Such feedback may take the form of a hiccup triggered in response to stimulation.
- stimulation can be targeted to one or more nerves to enhance, augment, inhibit or block signaling of efferent, afferent and/or interneuronal nerve cells, with any combination of these effects being within the scope of this disclosure.
- Stimulus can be directed to a mixed nerve containing both afferent and efferent nerve cells to produce one effect (e.g. enhance, inhibit or block signaling) on one type of nerve cell (i.e. the afferent or efferent nerve cells), and to produce the same or a different effect (e.g. enhance, inhibit, block, or yield a neutral effect) on the other type of nerve cell.
- stimulation can be delivered to one or more separate afferent nerves, efferent or interneuronal nerves nerves using the same or different electrodes/fluid conduits to trigger one of these effects (e.g. enhance signaling, inhibit signaling, block signaling, or have a neutral or any combination of the effects).
- effects e.g. enhance signaling, inhibit signaling, block signaling, or have a neutral or any combination of the effects.
- FIG. 5 illustrates the device 12 positioned in the IVC with the lead 14 extending into the peripheral vasculature (shown schematically) for delivery of therapeutic stimulus to peripheral nerves.
- peripheral nerve stimulation might be used to aid movement of a limb experiencing paresis due to peripheral neuropathy.
- a sensor is positioned proximal to the site of the nerve damage. When the sensor detects nerve signals indicating that the patient is attempting to move the limb, the electrode is energized to stimulate nerve(s) distal to the nerve damage. The sensed signal may be detected from the damaged nerve at a location proximal to the nerve damage, and the stimulus may be delivered to the damaged nerve ata location distal to the nerve damage, effectively creating a “bridge” across the nerve damage.
- Lead 14 may similarly function to bridge neural interruptions in a limb that has been reattached.
- the lead 14 extends through a blood vessel beyond the point of reattachment so that the electrode is positioned to deliver stimuli to nerve(s) distal to the reattachment. This may require surgical microconnections of the lead 14 to specific areas within the cross-section of the proximal and distal nerve segments.
- the lead 14 may extend into the prosthetic limb of an amputee.
- the signals detected by sensor(s) positioned in the body are used to trigger delivery of signals to the prosthesis instructing the prosthesis to move a particular way.
- the prosthesis can be configured to select from a preprogrammed menu of movement types based on the nature of the sensed signals.
- an electrical or fluid lead positioned in the peripheral vasculature might also be used to for maintenance of the implant.
- a fluid lead might include a port into which agents may be injected using a percutaneous syringe in order to refill a fluid reservoir in the device 12 .
- An electrical lead might include features for transcutaneous recharging of the battery in the device, such as inductive charging, optical charging (e.g. using a light source that transmits light through the skin for impingement onto photovoltaic cell(s) on the lead) or mechanical charging (e.g. transmitting mechanical vibrations through the skin to a piezoelectric element on the lead).
- FIGS. 6 through 13 Additional exemplary methods for use of an intravascular system of the type disclosed herein are shown in FIGS. 6 through 13 .
- FIGS. 6 and 7 illustrate use of an implantable stimulator for treatment of congestive heart failure (“CHF”).
- CHF congestive heart failure
- neurohumoral compensatory mechanisms are activated to maintain circulatory stability in a state of low cardiac output.
- Neurohumoral activation particularly activation of the sympathetic nervous and renin-angiotensin-aldosterone systems, works to maintain arterial pressure (via vasoconstriction) and restore cardiac output (by increasing myocardial contractility, heart rate, and intravascular volume).
- Such compensatory mechanisms are beneficial in the short-term, but can become pathologic over time.
- Persistent neurohumoral activation contributes significantly to the progressive cardiovascular dysfunction seen in patients with CHF. For example, inappropriate activation of the renin-angiotensin-aldosterone system in CHF promotes salt and water retention in the absence of hypovolemia, increasing preload and increasing myocardial energy requirements on an already-failing heart.
- the autonomic nervous system regulates blood pressure by augmenting the tonic rate of sympathetic discharge to smooth muscle in the blood vessel wall.
- This tonic sympathetic stimulation establishes and maintains vessel tone.
- Increasing sympathetic discharge causes vasoconstriction, which increases total peripheral resistance (TPR) and therefore increases blood pressure.
- TPR total peripheral resistance
- Decreasing sympathetic discharge causes vasodilation, which decreases TPR and therefore decreases blood pressure.
- Sympathetic and parasympathetic vasodilator innervation of blood vessels does not play a significant role in determining TPR.
- Baseline TPR is established and maintained via tonic sympathetic outflow from the medullary vasomotor center (MVC) in the rostral ventrolateral medulla (VLM).
- MVC medullary vasomotor center
- VLM rostral ventrolateral medulla
- the MVC is the primary site for integration of autonomic regulation of the cardiovascular system.
- the MVC has reciprocal connections with higher CNS centers (hypothalamus, cerebral cortex) and lower CNS centers (spinal cord nuclei), and additionally receives sensory input from baroreceptors and chemoreceptors.
- the baroreceptor reflex pathway triggers rapid compensation for changes in arterial pressure.
- Baroreceptors high-pressure mechanoreceptors in the carotid sinus, aortic arch, heart, and lungs sense blood pressure as “stretch” in the vessel wall.
- Primary afferent neurons arising from baroreceptors project via the vagal and glossopharyngeal nerves to the nucleus tractus solitarius (NTS).
- NTS nucleus tractus solitarius
- Excitatory output from the NTS projects to the nucleus ambiguus (vagal motor nucleus) and to the caudal VLM, which activates GABAergic interneurons to relay inhibitory signals to the rostral RVM.
- Efferent projections include 1) inhibitory vagal projections to the heart and 2) sympathetic efferent projections from the RVM to the heart and vasculature via the interomedial column of spinal cord (IML) and sympathetic ganglia.
- Changes in afferent (baroreceptor) firing frequency are mirrored in vagal efferent firing frequency, and reversed in sympathetic efferent firing frequency.
- Reflex changes in TPR are governed solely by sympathetic activity.
- Reflex changes in heart rate are determined by the balance between vagal and sympathetic efferent activity.
- Increased arterial pressure causes an increase in baroreceptor firing frequency, which increases inhibitory signaling to the brain stem. This inhibition decreases sympathetic outflow, which causes vasodilation and decreases heart rate, and also increases parasympathetic outflow, which decreases heart rate.
- the net result of the autonomic response to increased arterial pressure is therefore a rapid, compensatory drop in blood pressure.
- Decreased arterial pressure causes a decrease in baroreceptor firing frequency, which decreases inhibitory signaling to the brain stem. This increases sympathetic outflow, which causes vasoconstriction and increasing heart rate, and also decreases parasympathetic outflow, which increases heart rate. These effects combine to increase cardiac output and TPR to prevent further decreases in blood pressure and therefore maintain adequate perfusion to vital organs.
- Persistent activation of the sympathetic nervous system begins in the early stages of CHF, and plays a significant role in the natural history of the disease. Such sympathetic “overdrive” attempts to compensate for reduced cardiac output but ultimately accelerates the progression of the underlying ventricular dysfunction.
- High circulating levels of norepinephrine (NE) induce down-regulation or cardiac ⁇ -adrenergic receptors, which impairs cardiac inotropic and chronotropic response.
- NE release is increased while re-uptake is decreased.
- ⁇ 2-receptors which normally inhibit NE release, are down-regulated.
- Increased circulating NE levels in heart failure have been implicated in pathologic ventricular remodeling and also in ventricular arrhythmias. Plasma NE levels directly correlate with disease severity and mortality rate in patients with CHF.
- CHF treatment is achieved using neurostimulation of features of the peripheral nervous system to alter signals sent from baroreceptors of the arterial system to the central nervous system to trigger vasodilation and to thus decrease the heart's workload.
- the neurostimulation is directed towards the central nervous system so as to alter signals sent from the central nervous system to prevertebral and para vertebral sympathetic ganglia.
- the method illustrated in FIG. 6 treats CHF by stimulating baroreceptors in a manner that causes them to behave as they would when stimulated through expansion of the associated vessel due to an increase in arterial pressure, i.e. so that the baroreceptor produces inhibitory signals that trigger decreases in sympathetic tone, peripheral vascular resistance. and afterload.
- Targeted baroreceptors include those in and/or around the heart and large vessels.
- Tables 1 and 2 lists both barorecepter (mechanoreceptors) and chemoreceptors that might be targeted using electrical and/or chemical stimulation using the disclosed embodiments.
- Chemoreceptors proper sensitive to ⁇ P a O 2 , also sensitive to ⁇ pH or ⁇ P a CO2 (esp. carotid body)
- Peripheral chemoreceptive cells vagal-mediated or sympathetic- mediated; opposing pathways triggered in same local region by short- lived chemicals (bradykinin, prostaglandins) produced by hypoxic tissue Juxtapulmonary capillaries, alveolar interstitium (J receptors; pulmonary depressor chemoreflex) Coronary vasculature (coronary depressor chemoreflex) and left ventricular wall Right ventricle Atria Great veins Pulmonary artery Aorta Central chemoreceptors CNS osmoreceptors (stimulate ADH secretion) located in hypothalamus Persistent hypoxia ⁇ increase sympathetic output from medullary vasomotor center
- electrical stimulation lead 14 extends superiorly from the device 12 and is electrically coupled to electrode anchor 16 b , which includes a plurality of stimulating electrodes 26 positioned to contact the vessel walls upon expansion of the anchor 16 b .
- the lead 14 and electrode anchor are positioned such that the associated electrodes are within the internal jugular vein at the level of the carotid bifurcation. This positioning allows the electrodes to stimulate the carotid baroreceptors located in the carotid sinus adjacent to the internal jugular vein.
- Multiple leads may be positioned at various baroreceptor locations for multi-site stimulation.
- stimulation may instead or additionally be directed to afferent neurons that carry signals from the baroreceptors to the central vasomotor center via the glossopharyngeal nerve (which innervates the baroreceptors of the carotid sinus) or the vagus nerve (which innervates the aortic arch baroreceptors), for the purpose of enhancing the inhibitory signaling of the baro-receptors.
- Inhibition of the central vasomotor center can also be increased by simulating baroreceptors in the atria or ventricles (e.g. through the use of electrode leads situated in the heart), or by stimulating baroreceptors within the lungs, and/or by positioning the leads such that they will stimulate the afferent vagal neurons that carry inhibitory signals from these baroreceptors to the brain.
- stimulation is preferably delivered in response to feedback from one or more sensors positioned on the implant itself, on a separate implant, or located external to the body.
- Parameters that might be detected include but are not limited to: (a) heart rate and/or Q-T interval determined using an electronic sensor on the device body or lead or external to the body; (b) aortic blood pressure and/or pulmonary artery blood pressure, measured using one of various intravascular pressure sensing techniques known in the art, including capacitive pressure sensors, piezoelectric pressure sensors, temperature differential pressure sensor, flow sensors, etc.; (c) left ventricular chamber dimension determined using echo ultrasound, or measurement of impedance between two closely spaced electrodes within the heart (i.e.
- cardiac output using a combination of chamber dimension as determined in (c), plus flow, and heart rates measured using conventional means;
- the system might also be responsive to feedback from sensors capable of detecting biochemical markers associated with CHF.
- markers targeted for detection might include:
- TNFa tumor necrosis factor
- BNP Brain Natriuretic Peptide
- the carotid baroreceptor may instead be stimulated in a manner that afferent signaling from the baroreceptor indicates increased stretch of the vessel causing the body's feedback control system to believe there is a volume overload condition and thus triggering the efferent signaling to trigger increased natural diuresis.
- electrical stimulation patterns would be chosen to achieve the desired effect while at the same time selectively blocking the downstream vasodilation effects.
- the embodiment shown in FIG. 6 includes drug delivery leads 14 b , 14 c for delivering suitable agents into the blood within the vasculature and/or the heart.
- the system may be used to deliver agents used to treat symptoms of congestive heart failure (CHF), including cardio-renal syndrome.
- agents may include agents within the classes of positive inotropes, diuretics, vasodilators, and cytokine effectors.
- Specific agents include: Dobutamine, Atrial Natriuretic Peptide, Digoxin, Enoximone, Nesiritide, Tezosentan, Bumetanide, Hydralazine, Alprostadil, Carvedilol, Enalaprilat, Ambrisentan, and Levosimendan (sold by Abbott Laboratories under the trade name Simdax).
- the leads 14 b , 14 e are coupled to a drug reservoir/pump 40 .
- the leads are positionable to deliver drugs to the kidneys, however, the leads may alternatively be positioned elsewhere in the cardiovascular system, including within the heart.
- a two-device configuration like that of FIG. 1C may be used so that electrodes can be positioned in the internal jugular as shown in FIG. 6 as shown, while a separate drug delivery device can be positioned in the aterial system. This allows drug delivery leads 14 b , 14 c to be anchored in the renal arteries, allowing blood flood to propel drugs from the leads to the kidneys.
- the neurostimulation device is used to stimulate the central nervous system in order to augment autonomic control of peripheral vascular resistance.
- the benefits achieved using this embodiment are suitable for treatment of congestive heart failure, as well as hypertension (essential and secondary), diabetes mellitus, and other conditions.
- Stimulation may be targeted to one or more of a variety of neurological targets in the brain.
- stimulating electrodes are positioned in the brain to deliver electrical stimulus that will inhibit the vasomotor center in the rostral ventro-lateral medulla (“RVLM”).
- the vasomotor center in the RVLM can be inhibited by low-level electrical stimulation to, for example, inhibitory fibers to the nucleus tractus solitarius, and/or stimulation of GABAergic interneurons projecting to the RVLM.
- an electrode lead can be passed through the subclavian vein and the jugular vein, and then guided to, for example, a superficial cranial vein.
- the surgeon palpates the skin to find the lead, forms a small incision to gain access to the lead, threads the lead through a treephine hole drilled into the skull, and advances the lead towards the target area within the brain.
- the target area may be determined prior to device implantation using direct electrical stimulation of the brain.
- the electrical energy may be conducted transvenously through the vessel walls towards the neurological target without penetration of the vessel wall.
- Access to the neurological target for direct or transvenous stimulation can be gained via veins of the posterior fossa, the petrosal sinus and petrosal veins, the vein of the middle cerebellar peduncle, the lateral medullary and other medullary veins, the retro-olivary vein, regional bridging veins, as well as through other vessels.
- stimulation may be used to inhibit efferent neurons from the vasomotor center.
- stimulation energy can be delivered to any point along the pathway between (and including) the vasomotor center and the prevertebral and paravertebral sympathetic ganglia.
- FIGS. 8A through 11 illustrate methods for using an intravascular stimulation device for treatment of sleep apnea.
- the systems used in carrying out these methods preferably deliver stimulation upon receipt of feedback indicative of a cessation in breathing.
- Various parameters can be sensed for this purpose, including but not limited to: (a) breathing movements using an accelerometer to detect chest movement or a strain gauge to detect chest expansion; (b) changes in lung volume using impedance plethysmography to measure transthoracic impedance changes; (c) changes in breathing efficiency using an intravascular chemical sensor for detecting blood CO2 or O2 concentrations; (d) sleep state using EEG electrodes positioned on the scalp or within the brain; (e) facial movements, especially rapid eye movement, using an accelerometer; (f) snoring using acoustic detection methods; (g) muscle tone of specific throat structures using electrodes; (g) changes in airway flow rates and pressures to monitor airway patency.
- the FIG. 8A embodiment uses phrenic nerve stimulation as a means for treating sleep apnea.
- phrenic nerve stimulation in response to detection of a threshold CO2 level by a CO2 sensor 60 positioned on the device 12 or lead 14 , one or more stimulating pulses are delivered to the phrenic nerve, causing contraction of the diaphragm to expand the lungs and to thus draw air into the lungs.
- Similar device positioning might also be used for diaphragmatic pacing to facilitate breathing in patients having neurological injuries or disorders, such as motor neuron disease and spinal cord injury, among others.
- Devices for diaphragmatic pacing might include features allowing for rate adaptive breathing rate modulation, allowing pacing to be responsive to feedback from one or more sensors indicating various metabolic needs. Suitable sensors include, for example, accelerometers for detecting patient motion, heart rate monitors, and pCO 2 and pO 2 sensors.
- electrodes are anchored in the left and right subclavian veins, near the phrenic nerves.
- electrodes may be positioned directly in contact with the phrenic nerve by extending an electrode lead 14 through an opening O formed in a wall of a blood vessel, preferably at a location near the phrenic nerve.
- a vascular sealing member or substance 62 may be used to close the opening O in the region surrounding the lead to minimize bleeding.
- the lead is positioned in contact with the phrenic nerve, or embedded within the nerve tissue, such that by energizing the electrode the nerve may be directly stimulated.
- the lead may be positioned within an intact vessel (e.g. a subclavian vein) at a point at which the vessel crosses the phrenic nerve, thus allowing conduction of the electrical stimuli from the electrode through the vessel to the phrenic nerve.
- an intact vessel e.g. a subclavian vein
- FIG. 9 shows an alternative electrode arrangement suitable for treating sleep apnea.
- electrodes are positioned such that stimulation energy passes transvenously through the walls of blood vessels that are in electrical contact with the diaphragm, thus stimulating the diaphragm.
- Electrodes may be positioned in the right and left hepatic veins as shown, or in any other sites including but not limited to the inferior vena cava.
- this embodiment is also suitable as a diaphragmatic pacer to facilitate breathing in patients having motor neuron disease, spinal cord injury, or other diseases/conditions.
- electrical stimulation is delivered to the hypoglossal nerve, which innervates the muscles of the tongue.
- This embodiment may be useful for treating obstructive sleep apnea in a patient whose tongue relaxes during sleep to a point at which the tongue causes an obstruction of the airways. Stimulating the hypoglossal nerve can increase the tone of the muscles of the tongue, thus opening the airways.
- energy is conducted to the hypoglossal nerve using electrddes anchored in the left and right internal jugular veins, near the points where those veins cross the left and right hypoglossal nerves.
- the electrodes may be positioned to stimulate the oropharyngeal muscles or the nerves that innervate them, so as to contract those muscles away from the airway.
- lead 14 may be extended into the brain (for example, as described in connection with FIG. 7 ) for deep brain stimulation as shown in FIG. 11A .
- Routes for passage of the lead into the brain include, but are not limited to, the facial vein and the retro-mandibular vein.
- FIG. 11B illustrates positioning of the device 12 in the inferior vena cava, with the lead 14 extending superiorly towards the brain.
- the disclosed system may be used to deliver vagus nerve stimulation for treatment of various diseases or conditions, including but not limited to epilepsy, depression, Alzheimer's disease, anxiety disorders (for example, obsessive compulsive disorder), tourette syndrome, bulimia, and obesity.
- the FIG. 12 embodiment illustrates positioning of stimulation electrodes in the internal jugular vein at a location from which energy from the electrodes can be conducted through the jugular vein to the left vagus nerve. Alternate electrode positions might also be used, including the superior vena cava and the brachio-cephalic veins, among others.
- FIG. 12 illustrates transvenous stimulation of the nerve, it should be appreciated that with any of the disclosed embodiments, direct stimulation may instead be employed by passing the lead through the vessel wall and positioning it in contact with the target neural structure.
- Neurostimulation of cardiac parasympathetic nerves and plexuses may be used to treat multiple types of aberrant heart rates and rhythms.
- a neurostimulation system is used for ventricular rate control during atrial fibrillation.
- the electrode is positioned within the superior vena cava or in an alternate location from which it can be used to stimulate adjacent cardiac parasympathetic nerves to achieve ventricular rate control during atrial fibrillation.
- Operating parameters may be selected to deliver high-frequency (e.g. on the order of 50-250 Hz) nerve stimuli during the atrial refractory period, thus preventing atrial excitation during the adjacent nerve stimulation.
- Neurostimulation of cardiac parasympathetic nerves and plexuses may be accomplished either directly or transvenously, and may be performed at multiple sites, including but not limited to the superior vena cava, the inferior vena cava, and the coronary sinus.
- Suitable applications for use of these devices/systems include, but are not limited to:
- Deep brain stimulation or cortical stimulation (alone or in combination with drug delivery to the stimulated area) for treatment of motor disorders including essential tremor, Parkinson's disease, Dystonia, for stroke rehabilitation, as well as other neurological disorders including obsessive conpulsive disorder.
- motor disorders including essential tremor, Parkinson's disease, Dystonia, for stroke rehabilitation, as well as other neurological disorders including obsessive conpulsive disorder.
- epilepsy depression, mood disorders, anxiety disorders, pain and tinnitus.
- Stimulation might be delivered to regions of the brain (e.g. the insula) to control addiction to substances or behavior.
- Occipital nerve stimulation for treatment of headaches
- VNS Vagus nerve stimulation
- PNS Peripheral nerve stimulation
- SCS Spinal cord stimulation
Abstract
The present disclosure describes intravascular systems that may be used for a variety of functions. The elements of the disclosed systems include at least one device body implanted within the vasculature. Electrodes on a lead and/or on the device body itself are used to direct electrical energy to neurological targets. These systems may additionally include one or more fluid reservoirs housing drugs or other agents to be delivered to tissue.
Description
- This application is a continuation of co-pending U.S. Ser. No. 11/702,000, filed Feb. 2, 2007, which claims the benefit of U.S. Provisional Application No. 60/765,420, filed Feb. 3, 2006.
- The present invention generally relates to implantable devices and systems, and associated methods for delivering therapy to the neurological system.
- “Neuromodulation” is the therapeutic alteration of activity in the central, peripheral or autonomic nervous systems, electrically and/or pharmacologically, by means of implanted devices. Implantable medical devices are used to deliver neuromodulation therapy to patients to treat a variety of symptoms or conditions. For example, some the implantable medical devices deliver neurostimulation therapy in the form of electrical pulses. For some conditions, electrical stimulation is performed in combination with drug therapy using implantable drug pumps that deliver drugs to the nerves undergoing neurostimulation.
- U.S. Publication No. US2005/0043765 (“765 publication”) Intravascular Electrophysiological System and Methods (filed Jun. 4, 2004 and commonly owned with the present application), which is incorporated herein by reference, describes intravascular systems that may be used to deliver electrical energy to the heart such as for defibrillation, pacing, and/or cardioversion of the heart.
- Such systems include at least one housing containing the necessary pulse generator and associated electronics, circuitry and related components, and they optionally include at least one lead carrying some or all of the electrodes needed to deliver the electrical energy to the body. Some or all of these components are positioned within the vasculature, such as in the superior vena cava (“SVC”), the inferior vena cava (“IVC”), the left or right subclavian vein (“LSV” or “RSV”), coronary sinus and/or within other vessels in the venous or arterial system. For some of the implant components (such as the housing and/or lead), anchoring devices may be needed to retain the implant within the vasculature.
- U.S. Publication No. 2005/0234431 (“431 publication”), Intravascular Delivery System for Therapeutic Agents (filed Feb. 10, 2005 and commonly owned with the present application), which is incorporated herein by reference, describes systems for intravascular drug delivery system. Certain ones of the embodiments of the described systems include a reservoir implantable within a blood vessel, an intravascular pump fluidly coupled to the reservoir and an
anchor 16 expandable into contact with a wall of the blood. vessel to retain the system within the vasculature. Delivery conduits 108 (FIG. 11 of the '43.1 publication) may extend from the reservoir and are positionable at select locations within the vasculature for target drug delivery to select organs or tissues. Throughout this disclosure, the terms “drugs” and “agent” will be used to refer to any substances to be delivered into the body for any purpose including, but not limited to, prophylactic or therapeutic purposes. In some cases, such substances might also be biologic, such as vector-directed or mediated gene therapy, microspheres containing releasable agents, or stem cells modified to express certain proteins or other therapeutic or diagnostic compounds. - As disclosed in each of the above-referenced applications as well as U.S. Publication No. 2006/0217779 Flexible Hermetic Enclosure for Implantable Medical Devices (filed Mar. 24, 2005 and commonly owned with the present application), which is incorporated herein by reference, these types of implantable devices may be long and narrow for implantation into the vascular, and in some cases can be approximately 10-60 cm in length. Such devices are preferably sufficiently flexible to move through the vasculature yet sufficiently rigid to protect the internal components. Certain embodiments described in the above-referenced patent applications build flexibility into the elongate implants by assembling them using a plurality of segments, with each segment defining interior space for components to be housed within it. Each segment may be separately enclosed by its own enclosure, with several such enclosures coupled together to form the implant. The enclosures are interconnected at articulations formed using silicone rubber filler or mechanical bellows.
- It is believed that intravascular devices of the type described in the referenced applications may be suitable for use as neuromodulation devices to delivery electrical and/or pharmaceutical therapy to the nervous system.
-
FIGS. 1A-1C are block diagrams showing three exemplary embodiments of neurostimulation systems. -
FIGS. 2A and 2B are plan views showing implantable neurostimulation components and associated implant tools. -
FIG. 3 is a plan view of an implant showing flexible interconnects between portions of the implant. -
FIG. 4A is a perspective view showing an anchor. -
FIG. 4B is a cross-section view taken along the plane designated 4B-4B inFIG. 4A . -
FIG. 4C is a side elevation view of the anchor ofFIG. 4A mounted on an implant device and compressed by a sheath. -
FIG. 4D schematically illustrates use of the anchor ofFIG. 4C to support the implant device within the inferior vena cava. -
FIGS. 5-13 are schematic illustrations showing the heart and associated vasculature, and illustrating placement of neurostimulation devices within the body. - Generally speaking, the present disclosure describes intravascular systems that may be used for a variety of functions. In general, the elements of the systems described below include at least one device body and typically, but optionally, at least one lead coupled to the body. The device body (which may include a number of body segments coupled to one another) is ideally positioned fully within the vasculature of the patient. Electrodes on the lead and/or on the device body itself are used to direct monopolar or bipolar electrical energy to neurological tissue or associated structures. These systems may additionally include one or more fluid reservoirs housing drugs or other agents to be delivered to tissue. If drug delivery in combination with electrical therapy is contemplated, the lead(s) may include fluid conduits positioned to direct drugs/agents towards the area of the nervous system that is to be stimulated. Combined delivery of electrical stimulation and drugs/agents might also be used to activate a drug, or to treat a tissue to create an electroporation of a cell to make it more receptive to the administered drug, or to release drugs from drug-containing microspheres having walls that burst or increase in porosity when subjected to electrical stimulation. In other embodiments, neurostimulation is provided using agents (e.g. local application of neurotransmitter, neurotransmitter receptor agonists, neurotransmitter receptor antagonists, or other agents to nervous system target) with or without the use of electrical pulses. Electrical stimulation and/or drug delivery can also be directed to other neurological or non-neurological targets (including organs and/or associated systems) to simulate the release or inhibition of naturally produced agents such as adrenaline or insulin.
- Separate fluid delivery leads may also or alternatively be used to direct drugs/agents to an organ (e.g. kidneys, heart) or to other sites remote from the neural tissue undergoing stimulation. One or more anchors/retention devices may facilitate retention of the device body and/or leads or other elements within the vasculature.
-
FIGS. 1A through 1C are block diagrams illustrating three exemplary intravascular neurostimulation systems. In thefirst system 100 shown inFIG. 1A ,neurostimulation implant device 12 houses apower source 11 which may include a battery and a power generation circuit to produce operating powerstimulation.Device 12 also includes apulse generator 13 for generating stimulation pulses for transmission to the patient viaelectrodes 25 onleads 14 or directly on the body of theimplantable device 12. Aprocessor 30 may be included for controlling operation of thedevice 12. - Various stimulation parameters may be used depending upon the target structure and therapeutic application. In general, pulse sequences may use one or all of the following parameters: amplitudes within the range of approximately 1 to 50 mAmp, pulse widths of 1 to 1000 μs, burst rates of 1 to 500 Hz, and programmable duty cycles of 1% to 100%. For some applications, continuous electrical stimulation may be used, or pulse sequences having pulses of different parameters might be employed (e.g. for ventricular rate control in atrial fibrillation, the system might deliver pacing pulses and high-frequency neurostimulation during the atrial refractory period to prevent atrial excitation). The parameters may vary (e.g. ramp up or down) within a pulse sequence, or remain constant. Charge balancing of pulses is appropriate for preventing corrosion/electrolysis of the leads within the tissue. This is generally accomplished using wave forms having biphasic morphology or timing the capacitor recharge cycles such that there is no net imbalance of charge following stimulation.
- The functionality of the
system 100 may be enhanced using one or a combination of several additional features. For example, thesystem 100 may include a battery that is rechargeable. Anexternal charger 32 positioned outside the patient inductively couples to a chargingcircuit 33 within thedevice 12 to recharge the battery. Theexternal charger 32 includes a charging coil energizable to create an electromagnetic field that in turn induces current in a corresponding coil within the chargingcircuit 33. The coil may be mounted to a waist pack, wearable skin-contacting/adhering patch, purse, backpack, or wheelchair cushion so that it can be carried by the patient in sufficient proximity to the chargingcircuit 33. Alternatively, the coil may be positioned within a pad positionable on a patient's mattress, allowing for charging of the battery while the patient rests. - In other embodiments,
external charger 32 might be replaced with an external inductive power supply for transcutaneously powering the pulse generator whenever stimulation therapy is to occur, thereby obviating the need for the battery. Energy harvesting techniques may be used by which energy generated by the body may be converted for use in charging the battery and/or operating the system. Piezoelectric elements mounted at various locations in the body might, for example, be used to convert motion of the heart, pulsing blood vessels, limbs, or other structures to electrical energy. - The
system 100 may also include anexternal programmer 34 that communicates with atelemetry interlace 36 within theimplantable device 12 using radio frequency encoded signals or other telemetric methods. Telemetry systems permitting external devices to communicate with implanted medical devices are known in the art. See, for example, U.S. Pat. Nos. 6,824,561, 5,312,453 and 5,127,404. A user may use theprogrammer 34 to configure the device 12 (e.g. to set dosing schedules, to set the thresholds above/below which stimulation will be given, to set stimulation parameters), to review the history of therapy given by the implant, to test the implant, to allow the patient to direct release of analgesics for pain control, etc. Where multiple electrodes are employed, theprogrammer 34 may be used to identify the most optimal electrode pair for stimulating the target structure as discussed in greater detail below. -
Sensors 38 can be positioned for detecting certain conditions of the patient and for transmitting signals indicative of the sensed conditions. Signals corresponding to the sensed conditions may be used to trigger the delivery of therapy (see “Control Mechanisms” below) and/or sensor output may be stored within the device for subsequent retrieval usingexternal programmer 34. -
Sensors 38 may be located on thedevice body 12 or theleads 14, or coupled to thedevice body 12 or leads 14 using cables. For some applications,sensors 38 a may be separate implantable or extracorporeal components having communication features allowing them to communicate with theimplant 12 via thetelemetry interface 36 and/or with external.programmer 34. -
FIG. 1B shows a second system 10 a that differs from the system ofFIG. 1A in the incorporation of a drug delivery reservoir and pump features 40 allowing administration of drugs from the reservoir to drug leads 14 a (e.g. microtubules) extending from the device. These drug delivery features may be enclosed within the same housing occupied by the other components, or the drug delivery components and neurostimulation components may be divided into two or more separate housings electronically coupled to one another. It should be noted that theFIG. 1A embodiment may be altered to provide only drug delivery, such as for neurostimulation using agents only (e.g. neurotransmitter, neurotransmitter receptor agonists, neurotransmitter receptor antagonists, analgesics), without the use of electrical stimulation. - The
system 100 b ofFIG. 1C is similar to the system ofFIG. 1B , but differs in that the neurostimulation features and drug delivery features are contained within physically separate housings. According to this embodiment, the drug reservoir and pump features 40 are enclosed within acontainer 42 having itsown power source 44 as well as communication features 46 for receiving signals wirelessly transmitted by thetelemetry interface 36 in thedevice 12 b. With this arrangement operation of the drug delivery pump can be governed wirelessly by the processor housed in thedevice 12 b in a master-slave type configuration. In variations on this embodiment, the arrangement of components might be reversed such that thedevice 12 b includes the slave components remotely controlled by a processor within thecontainer 42. In another variation, both the neurostimulation components of thedevice 12 b and the drug delivery components of thecontainer 42 are wirelessly controlled using a third device implanted within the body (e.g. in the vasculature or in a subcutaneous location) or positioned external to the body. Other systems might employ multiple neurostimulators and/or drug delivery devices independently controlled or controlled using a common master device either directly or wirelessly. In yet another variation using separate drug delivery and neurostimulation implants, one or the other (or both) of the implants may be positionable outside the vasculature. -
FIGS. 2A and 2B illustrate exemplary neuromodulation devices and associated components for use in implantation and anchoring of the devices. - The elements of the
FIG. 2A system includeelongate device body 12, lead 14,retention device 16,sleeve 17, positioningmandrel 18 andintroducer sheath 19. It should be understood that certain of these elements may be eliminated, or others added. to the system, without departing from the spirit and scope of the invention. - As discussed in connection with
FIGS. 1A-1C ,device 12 houses components known in the art to be necessary to carry out the system functions. For example,device 12 may include one or more pulse generators, including associated batteries, capacitors, microprocessors. and/or circuitry for generating electrical stimulation pulses and/or drug reservoirs and associated pumps associated with drug delivery. The '431 publication provides examples of features drug reservoirs, pumps or other drug delivery mechanisms, and other features that may be included in a neuromodulation device having drug delivery capabilities. As discussed in greater detail in the section entitled “Control Mechanisms”,device 12 may include sensors and detection circuitry for detecting the onset of neurological episodes (e.g. seizures) or other conditions within the body, and/or it may be equipped to directly or wirelessly receive feedback signals from sensors positioned elsewhere inside or outside the body. The specific sensors and other components to be provided in the device will depend upon the application for the device. - The
device 12 is proportioned to be passed into the vasculature and to be retained within the patient's vasculature. Suitable sites for thedevice 12 may include, but are not limited to, the venous system using access through the right or left femoral vein or the subclavian or brachiocephalic veins, or the arterial system using access through one of the femoral arteries. Specific vessels within which the device can be retained include the superior vena cava, inferior vena cava, jugular vein, subclavian vein, axillary vein, and the iliac vein, amongst others. - If the device is to be positioned in an essential blood vessel, it is desirable to minimize obstruction to blood flow presented by the device. In that case, the transverse cross-sectional area of the implant is preferably <50% of that of the vessel. Thus, the housing of
device 12 preferably has a streamlined maximum cross sectional diameter which may be in the range of 1-15 mm or less, with a most preferred maximum cross-sectional diameter of 1-8 mm or less. The cross-sectional area of the device in the transverse direction (i.e. transecting the longitudinal axis) should be as small as possible while still accommodating the required components. This area may be within the range of 5-175 mm2. Other acceptable ranges of cross-sectional areas are those within the ranges of approximately 79 mm2 or less approximately 40 mm2 or less, or 12.5-40 mm2 - The cross-section of the device (transecting the longitudinal axis) may have a circular cross-section, although other cross-sections including crescent, flattened, or elliptical cross-sections may also be used. It is highly desirable to provide the device with a smooth continuous contour so as to avoid voids or recesses that could encourage thrombus formation on the device.
- Depending on the components to be included in the
device 12, the device may utilize a single- or multiple-compartment housing having a length in the range of 1-100 cm. - A proximal portion of the device includes a
connector 25 for receiving the distal end of positioningmandrel 18, which may be used to steer the device 12 (by pushing, pulling and/or torquing) through the patient's vasculature to a target location as described in detail in the above-referenced applications. Theconnector 25 may take the form of a threaded bore for receiving a threaded screw member at the distal end of themandrel 18, or it may have any other type of configuration for detachably engaging the distal end of the mandrel.Mandrel 18 can also function as an explant tool used to engage thedevice 12 and withdraw it from the body. -
Mandrel 18 may serve purely mechanical purposes, or it may also be a “smart mandrel” that provides electrical and/or fluid connections. Such connections can be used to couple the device (via an instrument cable) for electrical, electronic, and/or fluid communication between the device and instrumentation located outside the body. This communication may be used for several purposes, including device testing, initiation and/or programming during implantation, and/or recharging of the device battery. If the device is to be used for drug delivery, the mandrel may be used for re-filling a reservoir in the device with drugs/agents that may be deliverable by the device to a patient. - The position of the
lead 14 relative to the device is preferably selected to orient the lead in the direction of the vessels (relative to the vessel in which thedevice body 12 is positioned) that will receive thelead 14. In theFIG. 2A example, lead 14 is attachable to the inferior end of device 12 (thelead 14 may alternatively be integrally connected to the device).Lead 14 includes one ormore electrodes 26 configured to pass electrical energy through wall of the surrounding vessel into the targeted neurological structure or directly into the neurological tissue. - Including a number of separate electrodes (e.g. a longitudinal array of electrodes, which may number from 2-16 or more, or a two- or three-dimensional electrode grid such as a 4×4 grid) per lead can provide a number of advantages. For example, where many electrodes are provided, the system can electronically change which of electrodes in the array serves as the anode and which serves as the cathode, such that the effective site of stimulation can be moved without physical repositioning of the lead. The precise location of a neurological target may not always be known. With this capability, the system can sample various electrode pairs to evaluate which combination of electrodes will yield the most optimal response to stimulus. It is contemplated that such electronic manipulation of the electrodes can be done real time and continuously to provide for either isolated point stimulation using closely spaced electrodes or broad tissue capture using more widely separated electrodes. It is also contemplated that the movement of the stimulation site might be useful in managing/reducing damage or sensitization of local tissue to stimulation.
- Another advantage to the use of multiple electrodes or electrode pairs is that it allows for selective stimulation by means of using various electrode pairs to interfere with the propagation of electrical impulses in one direction while simultaneously (or sequentially) using separate electrode pairs to induce electrical stimulus propagation in the opposite direction along nerve fibers.
- Examples of electrodes that might be used include surface electrodes or tip electrodes. In other embodiments, electrodes that engage the walls of the surrounding vessel might be used. For example, an electrode may be an expandable electrode similar in structure to the
anchor 16, or theanchor 16 may be provided with multiple electrodes formed on or mounted to it. This type of embodiment might take the form of a polymeric stent-like grid with an array electrodes, each insulated from the other, throughout the grid structure. This arrangement allows stimulation to be delivered over a greater surface area (e.g. around the inner surface of a vessel wall) and might be particularly useful where the general location of the neurological tissue is known but the precise location is difficult to determine. As another example, the leads may include tip electrodes having penetrating elements that engage the vessel wall. For some applications, leads having electrode-bearing needle tips may be used to allow the electrode(s) to be passed through the vessel wall into the nerve or nerve bundle or to a superficial position from which the lead can be connected surgically to a remote target or a separate remote electrode. The needle tips may include features (e.g. barbs, helices, expandable anchors) that allow them to engage the surrounding neurological tissue. The leads might also be equipped to sense electrical activity of the target structures, such as for detecting the onset of a seizure. In such embodiment, activity sensed by the sensing electrode(s) may be used by the device electronics to trigger delivery of a neurostimulation pulse or one or more pulse sequences. - Additional leads may be provided if desired such that two or more leads may be positioned to stimulate neurological tissue at different locations. Where multiple leads are used, stimulation delivered by each lead may be simultaneous or sequential, or activation of each lead for delivery of therapy may be independent of activation of the other lead(s), with energization of each lead dependent on some sensed condition within the body. The neurostimulation leads may be provided alone or in combination with one or more drug delivery leads (e.g. conduits such as microtubules) positionable to deliver drugs or other agents to organs or other body tissues. Control of drug delivery may be timed to be contemporaneous with, sequential to, or independent of electrical stimulation.
- Electrical stimulation leads 14 may be conventional neurostimulation leads, although alternative lead configurations may be desirable if warranted by the desired placement of the
device 12 and lead within the body. Leads of the type used for defibrillation and/or pacing may be more suitable for some applications given their suitability for use in the vasculature. The physician will preferably want to select a location for thedevice 12 within a chosen vessel (e.g. the inferior or superior vena cava or aorta) that will prevent the device from blocking significant peripheral vessels extending from that vessel. An optimal lead will preferably give the physician implanting the device flexibility to position the device at an appropriate location in the chosen vessel without concern that the leads extending from the device will not reach their intended location, but will avoid leaving excess lead length bunched within the vasculature. Thus, for some patients it may be necessary to use a lead that is slightly shorter than defibrillation/pacing leads, or the lead may have a length that is variable/extendable using various techniques such as those described in the '765 publication. - The leads 14 and
device 12 may include coatings or coverings made of polymers such as polyurethane. The leads and device may also include non-thrombogenic and/or non-proliferative surfaces or coatings as also described in the referenced applications. For example, the leads and device body may include a coating that is anti-thrombogenic (e.g. perfluorocarbon coatings applied using supercritical carbon dioxide) so as to prevent thrombus formation on the lead. It is also beneficial for the coating to have anti-proliferative properties so as to minimize endothelialisation or cellular ingrowth, since minimizing growth into or onto the lead/device will help minimize vascular trauma when the device and/or lead is explanted. The coating may thus also be one which elutes anti-thrombogenic compositions (e.g. heparin sulfate) and/or compositions that inhibit cellular in-growth and/or immunosuppressive agents. - It should also be noted that the lead may be attachable to the
device 12 in situ or prior to implantation, or it may be permanently attached to the device, or it may be integral with the device as an elongate extension of the device itself. Thus it should be appreciated that in this disclosure the term “lead” is used to mean an element that includes conductors and electrodes and/or fluid lead conduits and that thus may be positioned somewhat remotely from the circuitry that energizes the electrodes or the reservoir that supplies agents to the fluid conduits. Thus, leads may include elements that are simply extensions or tapers of thedevice 12 itself (such as the superior portion of the device 12) as well as more conventional leads. - A second embodiment of a
device 12 and associated implant components is shown inFIG. 1B and differs from theFIG. 1A embodiment primarily in that itslead 14 is attachable (or integrally attached) to the superior end ofdevice 12. This arrangement might be suitable for use in delivering stimulus to features positioned superiorly relative to thedevice 12 position within the vasculature. - As further discussed in the '765 application, each of the leads may include a guidewire lumen to aid in implantation of the lead. Referring to
FIG. 1 , the system may includeguidewires 21 for use in implanting the leads. If multi-site stimulation and/or drug delivery is desired, two or more leads may be used. Devices for these applications may include both superior and inferior leads, multiple leads extending from the inferior and/or superior end, and/or leads extending laterally from the device body. Using separate neurostimulation and drug delivery implants as discussed in connection withFIG. 1C gives the user flexibility to deliver different forms of therapy to different regions of the body. For example, a system might include a neurostimulation device be positioned on the venous side of the cardiovascular system and a drug delivery system positioned within the arterial system. - As mentioned, where the
device body 12 is particularly long, the body should be sufficiently flexible to move through the vasculature while being sufficiently rigid to protect the internal components.FIG. 2 shows one example of aflexible device body 12 c which employs one or morerigid enclosures 50, or “containers,” used to contain electronic components to be implanted inside the vasculature of a patient. Thecontainers 50 house components known in the art to be necessary to carry out the system functions. For example, the containers within an implant device can collectively include one or more pulse generators, including associated batteries, capacitors, microprocessors, and/or circuitry for generating electrical pulses for neurostimulation, and or fluid reservoirs and associated pumps for drug delivery. The applications referred above provide additional information of these types of components, as well as suitable arrangements of these components within the device body. - Any appropriate number of the
containers 50 can be mechanically connected using interconnecting bellows 52 to form a flexible device. For many devices, this might include a string of at least three containers. The sequence of devices and linking bellows can be repeated as necessary to make a device of an appropriate length. For example, as shown inFIG. 2 , adevice 12 c may haveseveral containers 50 connected usingmultiple bellows 52 as needed to accommodate the components needed for performance of the device. Additional features of the containers and interconnection mechanisms are disclosed in the above-referenced applications. - The
neurostimulation implant device 12 is designed to be retained entirely within the vasculature. Retention within the vasculature can be achieved in one of several ways. For example, if positioned in a non-essential vessel, the device can be retained through frictional contact with the vessel wall. The flow of blood within a vessel can also be relied upon to retain the device in a vessel, preventing the device from migrating upstream while the physical structure of the vessel prevents downstream migration. In other embodiments, anchoring thelead 14 in a blood vessel (i.e. the same or a different blood vessel within which thedevice 12 is positioned) or outside the vasculature (e.g. through a vessel wall) will serve to retain the device which is coupled to the lead. In other embodiments including those illustrated inFIGS. 5 through 13 , an anchor in contact with thedevice 12 may be used to retain the device within a blood vessel. -
FIGS. 4A though 4D illustrate one example of ananchor 16 of the type that may be used to anchor thedevice 12 in the vasculature. Theanchor 16 is beneficial in that it is implanted integrally with the device, and thus does not require a separate implantation step. - Referring to
FIG. 4A ,anchor 16 includes structural features that allow the anchor to radially engage a vessel wall. For example, a band, sleeve, mesh or other framework formed of one or more shape memory (e.g. nickel titanium alloy, nitinol, thermally activated shape-memory material, or shape memory polymer) elements or stainless steel, Elgiloy, or MP35N elements may be used. The anchor may include anti-proliferative and anti-thrombogenic coatings, although in this embodiment theanchor structure 16 or adapted to promote tissue ingrowth to as to enhance anchor stability within the vessel. The anchor may also have drug delivery capability via a coating matrix impregnated with one or more pharmaceutical agents. -
FIG. 4B shows oneanchor 16 attached to adevice 12, although naturally one, two or more such anchors may alternatively be used. In one embodiment,anchor 16 is attached to theimplant 12 by a c-shapedcollar 54, or other suitable connection. Theimplant 12 may include a recessedportion 56 that allows the exterior of the anchor to sit flush with the exterior of theimplant 12 when the anchor is its compressed position. The recessed portion should have smooth contours in order to discourage thrombus formation on the device. - The
anchor 16 anddevice 12 may be detachably connected to the recessed portion using methods that allow theanchor 16 and theimplant 12 to be separated in situ, for permanent or temporary removal of theimplant 12. A detachable connection between theanchor 16 andimplant 12 may utilize a snap fit between thecollar 54 andimplant 12. As shown inFIG. 4B , both the collar and the recessed.portion 56 of the implant may include an elliptical cross-section. if it becomes necessary to remove the medical implant from the patient's body, the medical implant may be torqued about its longitudinal axis, causing the body of the implant to cam the edges of the collar to a slightly opened position, thereby allowing the implant to be passed between the edges of the collar. Other features of theanchor 16, as well as examples of alternative designs, are discussed in the '765 publication. - Referring to
FIG. 4C , aretractable sheath 17 may be slidably positioned over theanchor 16 and implant so as to retain the anchor in its compressed position. Retraction of the sheath as indicated inFIG. 4D allows theanchor 16 to expand into contact with the surrounding walls of the vessel, thereby holding the medical implant in the desired location. Once deployed, theanchor 16 is preferably intimate to the vessel wall, which is distended slightly, allowing the vessel lumen to remain approximately continuous despite the presence of the anchor and thus minimizing turbulence or flow obstruction. In other embodiments, the anchor may be deployed prior to thedevice 12, with the device later attached to the anchor, or it may be deployed after thedevice 12 with the anchor expandable to sandwich a portion of the device between the anchor and the vessel wall as disclosed in one embodiment of the '431 application. - Control Mechanisms
- The
device 12 delivers stimulation according to a control mechanism appropriate to the particular application for the device. Exemplary control mechanisms include but are not limited to the following: (a) open loop control, in which asynchronous stimulation is delivered without reference to sensor feedback (e.g. stimulation for pain control): (b) triggered control, in which no stimulation is delivered until a certain condition is detected and then asynchronous stimulation is initiated for a prespecified duration (e.g. stimulation to end an epileptic seizure), and (c) closed loop control, in which one or more feedback variables are actively monitored, and in which stimulator output is modified based on this feedback (e.g. stimulation for control of hypertension by balancing the reduction in heart rate vs elevation of blood pressure). A single system (e.g. any of the systems ofFIGS. 1A-1C ) can be equipped to use combinations of these control mechanisms for different forms of therapy to be delivered. For example, in a single system, closed loop control might be used for neurostimulation while open loop control is used for dnig delivery. - The sensing capabilities of the device will be tailored to the specific application(s) for use. Possible sensing capabilities for inclusion in the device include electrical sensing of physiologic parameters (e.g. heart rate, neurological activity), biochemical sensors for indicators of a given condition, chemical sensing of changes in hormone secretion, ionic balances (e.g. changes in sodium concentrations), or sensing of physical conditions (e.g. blood pressure, physical activity, volume over load, etc). The term “patient conditions” will be broadly used to refer to any type of state or condition that may be detected using a sensor, including but not limited to the sensors and states/conditions expressly identified herein.
- The sensors for feedback may be implantable or external, may be permanent or temporary, and may provide their feedback over large variations in sampling rate. They may be configured to transmit signals representing sensed physical/chemical/electrical parameters over the lead, over separate cabling, or through various wireless transmission techniques, or they might be imbedded in the device itself (e.g. a thermistor for core temperature measurements). Some specific types of sensors will be discussed in connection with the embodiments of
FIGS. 6-13 . - Some applications for the
system 10 involve positioning the electrodes at a location in a vessel such that stimulation pulses will conduct from the electrodes through the walls of the vessel to a target nerve located outside the vessel. Thesystem 10 may be provided with detection features allowing determination of the point at which the nerve and the vessel cross one another, so that electrodes nearest the crossing point may be activated for stimulation. Such features might include use of electrodes to monitor electrical pukes from the nerve, or to deliver mild stimulation during implantation so that specific feedback or patient reaction can be detected when the electrode is close to the nerve. For example, in the case of phrenic nerve stimulation, such feedback may take the form of a hiccup triggered in response to stimulation. - Exemplary Methods
- For use in performing neuromodulation, a system of the type described above would be positioned within the arterial, venous, or coronary vasculature or in the heart, with leads extending through the vasculature to locations from which electrical stimulus and/or drugs delivered from the leads will deliver a therapeutic benefit to the target neurological structures (such as nerves, the spinal cord, or target regions of brain tissue). For example, for deep brain stimulation, leads might be positioned to deliver therapy to deep brain structures such as the subthalamic nucleus and globus pallidus. In the case of epilepsy, electrodes might be passed through vessels leading to the region of seizure origin as determined by prior testing. Alternatively in the case of epilepsy, brain regions involved in seizures may be affected via stimulation of afferent fibers of the left vagus nerve by electrode(s) placed in cervical or thoracic vasculature.
- Where the device is used for electrical or drug stimulation of nerves, stimulation can be targeted to one or more nerves to enhance, augment, inhibit or block signaling of efferent, afferent and/or interneuronal nerve cells, with any combination of these effects being within the scope of this disclosure. Stimulus can be directed to a mixed nerve containing both afferent and efferent nerve cells to produce one effect (e.g. enhance, inhibit or block signaling) on one type of nerve cell (i.e. the afferent or efferent nerve cells), and to produce the same or a different effect (e.g. enhance, inhibit, block, or yield a neutral effect) on the other type of nerve cell. Alternatively, stimulation can be delivered to one or more separate afferent nerves, efferent or interneuronal nerves nerves using the same or different electrodes/fluid conduits to trigger one of these effects (e.g. enhance signaling, inhibit signaling, block signaling, or have a neutral or any combination of the effects).
-
FIG. 5 illustrates thedevice 12 positioned in the IVC with thelead 14 extending into the peripheral vasculature (shown schematically) for delivery of therapeutic stimulus to peripheral nerves. In one application, peripheral nerve stimulation might be used to aid movement of a limb experiencing paresis due to peripheral neuropathy. In this application, a sensor is positioned proximal to the site of the nerve damage. When the sensor detects nerve signals indicating that the patient is attempting to move the limb, the electrode is energized to stimulate nerve(s) distal to the nerve damage. The sensed signal may be detected from the damaged nerve at a location proximal to the nerve damage, and the stimulus may be delivered to the damaged nerve ata location distal to the nerve damage, effectively creating a “bridge” across the nerve damage.Lead 14 may similarly function to bridge neural interruptions in a limb that has been reattached. In this example, thelead 14 extends through a blood vessel beyond the point of reattachment so that the electrode is positioned to deliver stimuli to nerve(s) distal to the reattachment. This may require surgical microconnections of thelead 14 to specific areas within the cross-section of the proximal and distal nerve segments. In yet another example, thelead 14 may extend into the prosthetic limb of an amputee. The signals detected by sensor(s) positioned in the body are used to trigger delivery of signals to the prosthesis instructing the prosthesis to move a particular way. In this embodiment, the prosthesis can be configured to select from a preprogrammed menu of movement types based on the nature of the sensed signals. - Various other applications exist for the use of the disclosed neurostimulation systems to bridge neural interruptions at any level within the peripheral or central nervous system.
- It should be mentioned with reference to
FIG. 5 that an electrical or fluid lead positioned in the peripheral vasculature might also be used to for maintenance of the implant. Thus, a fluid lead might include a port into which agents may be injected using a percutaneous syringe in order to refill a fluid reservoir in thedevice 12. An electrical lead might include features for transcutaneous recharging of the battery in the device, such as inductive charging, optical charging (e.g. using a light source that transmits light through the skin for impingement onto photovoltaic cell(s) on the lead) or mechanical charging (e.g. transmitting mechanical vibrations through the skin to a piezoelectric element on the lead). - Additional exemplary methods for use of an intravascular system of the type disclosed herein are shown in
FIGS. 6 through 13 . -
FIGS. 6 and 7 illustrate use of an implantable stimulator for treatment of congestive heart failure (“CHF”). Before the details of theFIGS. 6 and 7 embodiments are given, some background on CHF and the body's response to the effects of CHF will first be described. - In patients with CHF, neurohumoral compensatory mechanisms are activated to maintain circulatory stability in a state of low cardiac output. Neurohumoral activation, particularly activation of the sympathetic nervous and renin-angiotensin-aldosterone systems, works to maintain arterial pressure (via vasoconstriction) and restore cardiac output (by increasing myocardial contractility, heart rate, and intravascular volume). Such compensatory mechanisms are beneficial in the short-term, but can become pathologic over time. Persistent neurohumoral activation contributes significantly to the progressive cardiovascular dysfunction seen in patients with CHF. For example, inappropriate activation of the renin-angiotensin-aldosterone system in CHF promotes salt and water retention in the absence of hypovolemia, increasing preload and increasing myocardial energy requirements on an already-failing heart.
- The autonomic nervous system regulates blood pressure by augmenting the tonic rate of sympathetic discharge to smooth muscle in the blood vessel wall. This tonic sympathetic stimulation establishes and maintains vessel tone. Increasing sympathetic discharge causes vasoconstriction, which increases total peripheral resistance (TPR) and therefore increases blood pressure. Decreasing sympathetic discharge causes vasodilation, which decreases TPR and therefore decreases blood pressure. Sympathetic and parasympathetic vasodilator innervation of blood vessels does not play a significant role in determining TPR.
- Baseline TPR is established and maintained via tonic sympathetic outflow from the medullary vasomotor center (MVC) in the rostral ventrolateral medulla (VLM). The MVC is the primary site for integration of autonomic regulation of the cardiovascular system. The MVC has reciprocal connections with higher CNS centers (hypothalamus, cerebral cortex) and lower CNS centers (spinal cord nuclei), and additionally receives sensory input from baroreceptors and chemoreceptors.
- The baroreceptor reflex pathway triggers rapid compensation for changes in arterial pressure. Baroreceptors (high-pressure mechanoreceptors in the carotid sinus, aortic arch, heart, and lungs) sense blood pressure as “stretch” in the vessel wall. Primary afferent neurons arising from baroreceptors project via the vagal and glossopharyngeal nerves to the nucleus tractus solitarius (NTS). Excitatory output from the NTS projects to the nucleus ambiguus (vagal motor nucleus) and to the caudal VLM, which activates GABAergic interneurons to relay inhibitory signals to the rostral RVM. Efferent projections include 1) inhibitory vagal projections to the heart and 2) sympathetic efferent projections from the RVM to the heart and vasculature via the interomedial column of spinal cord (IML) and sympathetic ganglia. Changes in afferent (baroreceptor) firing frequency are mirrored in vagal efferent firing frequency, and reversed in sympathetic efferent firing frequency. Reflex changes in TPR are governed solely by sympathetic activity. Reflex changes in heart rate are determined by the balance between vagal and sympathetic efferent activity.
- Increased arterial pressure causes an increase in baroreceptor firing frequency, which increases inhibitory signaling to the brain stem. This inhibition decreases sympathetic outflow, which causes vasodilation and decreases heart rate, and also increases parasympathetic outflow, which decreases heart rate. The net result of the autonomic response to increased arterial pressure is therefore a rapid, compensatory drop in blood pressure.
- Decreased arterial pressure causes a decrease in baroreceptor firing frequency, which decreases inhibitory signaling to the brain stem. This increases sympathetic outflow, which causes vasoconstriction and increasing heart rate, and also decreases parasympathetic outflow, which increases heart rate. These effects combine to increase cardiac output and TPR to prevent further decreases in blood pressure and therefore maintain adequate perfusion to vital organs.
- Persistent activation of the sympathetic nervous system begins in the early stages of CHF, and plays a significant role in the natural history of the disease. Such sympathetic “overdrive” attempts to compensate for reduced cardiac output but ultimately accelerates the progression of the underlying ventricular dysfunction. High circulating levels of norepinephrine (NE) induce down-regulation or cardiac β-adrenergic receptors, which impairs cardiac inotropic and chronotropic response. At adrenergic nerve endings, NE release is increased while re-uptake is decreased. α2-receptors, which normally inhibit NE release, are down-regulated. Increased circulating NE levels in heart failure have been implicated in pathologic ventricular remodeling and also in ventricular arrhythmias. Plasma NE levels directly correlate with disease severity and mortality rate in patients with CHF.
- In the
FIG. 6 embodiment, CHF treatment is achieved using neurostimulation of features of the peripheral nervous system to alter signals sent from baroreceptors of the arterial system to the central nervous system to trigger vasodilation and to thus decrease the heart's workload. In theFIG. 7 embodiment the neurostimulation is directed towards the central nervous system so as to alter signals sent from the central nervous system to prevertebral and para vertebral sympathetic ganglia. - The method illustrated in
FIG. 6 treats CHF by stimulating baroreceptors in a manner that causes them to behave as they would when stimulated through expansion of the associated vessel due to an increase in arterial pressure, i.e. so that the baroreceptor produces inhibitory signals that trigger decreases in sympathetic tone, peripheral vascular resistance. and afterload. - Targeted baroreceptors include those in and/or around the heart and large vessels. Tables 1 and 2 lists both barorecepter (mechanoreceptors) and chemoreceptors that might be targeted using electrical and/or chemical stimulation using the disclosed embodiments.
-
TABLE 1 Mechanoreceptor Locations in Reflex Pathways of Cardiovascular Regulation Inhibitory baroreceptors (most vagal-mediated) Arterial baroreceptors: adventitia of vessel wall in carotid sinuses (dilatation of vessel just above origin of internal carotid artery) adventitia of vessel wall of aortic arch Cardiopulmonary baroreceptors: atria, especially the right atrium, especially at cavoatrial junctions (SVC, IVC, pulmonary veins) but also diffusely distributed in atrial walls ventricular walls, left > right coronary vasculature pulmonary artery (main pulmonary artery and bifurcation) Excitatory baroreceptors (sympathetic-mediated) Diffusely (and somewhat sparsely) distributed throughout atria, ventricles, vena cavae, pulmonary artery, pulmonary veins, pericardium, and aorta (above diaphragm) -
TABLE 2 Chemoreceptor Locations in Reflex Pathways of Cardiovascular Regulation Chemoreceptors proper: sensitive to Δ PaO2, also sensitive to Δ pH or Δ PaCO2 (esp. carotid body) Carotid body Aortic Body Peripheral chemoreceptive cells: vagal-mediated or sympathetic- mediated; opposing pathways triggered in same local region by short- lived chemicals (bradykinin, prostaglandins) produced by hypoxic tissue Juxtapulmonary capillaries, alveolar interstitium (J receptors; pulmonary depressor chemoreflex) Coronary vasculature (coronary depressor chemoreflex) and left ventricular wall Right ventricle Atria Great veins Pulmonary artery Aorta Central chemoreceptors CNS osmoreceptors (stimulate ADH secretion) located in hypothalamus Persistent hypoxia → increase sympathetic output from medullary vasomotor center - In the illustrated embodiment,
electrical stimulation lead 14 extends superiorly from thedevice 12 and is electrically coupled toelectrode anchor 16 b, which includes a plurality of stimulatingelectrodes 26 positioned to contact the vessel walls upon expansion of theanchor 16 b. Thelead 14 and electrode anchor are positioned such that the associated electrodes are within the internal jugular vein at the level of the carotid bifurcation. This positioning allows the electrodes to stimulate the carotid baroreceptors located in the carotid sinus adjacent to the internal jugular vein. Multiple leads may be positioned at various baroreceptor locations for multi-site stimulation. - In a modification to the
FIG. 6 embodiment, stimulation may instead or additionally be directed to afferent neurons that carry signals from the baroreceptors to the central vasomotor center via the glossopharyngeal nerve (which innervates the baroreceptors of the carotid sinus) or the vagus nerve (which innervates the aortic arch baroreceptors), for the purpose of enhancing the inhibitory signaling of the baro-receptors. - Inhibition of the central vasomotor center can also be increased by simulating baroreceptors in the atria or ventricles (e.g. through the use of electrode leads situated in the heart), or by stimulating baroreceptors within the lungs, and/or by positioning the leads such that they will stimulate the afferent vagal neurons that carry inhibitory signals from these baroreceptors to the brain.
- According to the method of
FIG. 6 , stimulation is preferably delivered in response to feedback from one or more sensors positioned on the implant itself, on a separate implant, or located external to the body. Parameters that might be detected include but are not limited to: (a) heart rate and/or Q-T interval determined using an electronic sensor on the device body or lead or external to the body; (b) aortic blood pressure and/or pulmonary artery blood pressure, measured using one of various intravascular pressure sensing techniques known in the art, including capacitive pressure sensors, piezoelectric pressure sensors, temperature differential pressure sensor, flow sensors, etc.; (c) left ventricular chamber dimension determined using echo ultrasound, or measurement of impedance between two closely spaced electrodes within the heart (i.e. using impedance plethysmography determinations); (d) cardiac output using a combination of chamber dimension as determined in (c), plus flow, and heart rates measured using conventional means; (e) chemical sensors for detecting, sodium, calcium, various signaling hormones, AVO2 difference; blood pH (including as an indicator of lactic acid levels in the blood); blood gas levels (including blood 02 and/or blood CO2 levels). - The system might also be responsive to feedback from sensors capable of detecting biochemical markers associated with CHF. Some examples of markers targeted for detection might include:
-
- (a) Triage Cardiac—any combination of a unique set of three biochemical indicators of cardiac muscle necrosis: Mioglobine; CK-MB and Cardiac Troponine I; (b) Tumor Necrosis
- Factor. Elevated levels of the immune factor tumor necrosis factor (TNFa) may be very strong and accurate predictors of a poor outlook in CHF patients. This immune factor is known to be a potent agent in the intlammatory process; (c) C-Reactive Protein (d) Brain Natriuretic Peptide (“BNP”)—a non-invasive, objective marker of Congestive Heart Failure. With regard to BNP, research indicates that
-
-
- The concentration of BNP increases with the severity of CHF (precise correlation with NYHA classification).
- BNP concentration has the positive correlation with end-diastolic pressure in left ventricle.
- There is a reverse ratio between BNP level and the function of left ventricle after heart infarction.
- The increase of BNP level is associated with increasing of Pulmonary Artery Wedge Pressure (precise correlation), deterioration of LV diastolic and systolic functions, LV Hypertrophy and Heart Infarction.
-
- By using the same electrode location as shown in
FIG. 6 , the carotid baroreceptor may instead be stimulated in a manner that afferent signaling from the baroreceptor indicates increased stretch of the vessel causing the body's feedback control system to believe there is a volume overload condition and thus triggering the efferent signaling to trigger increased natural diuresis. In this example, electrical stimulation patterns would be chosen to achieve the desired effect while at the same time selectively blocking the downstream vasodilation effects. The embodiment shown inFIG. 6 includes drug delivery leads 14 b, 14 c for delivering suitable agents into the blood within the vasculature and/or the heart. For example, the system may be used to deliver agents used to treat symptoms of congestive heart failure (CHF), including cardio-renal syndrome. Such agents may include agents within the classes of positive inotropes, diuretics, vasodilators, and cytokine effectors. Specific agents include: Dobutamine, Atrial Natriuretic Peptide, Digoxin, Enoximone, Nesiritide, Tezosentan, Bumetanide, Hydralazine, Alprostadil, Carvedilol, Enalaprilat, Ambrisentan, and Levosimendan (sold by Abbott Laboratories under the trade name Simdax). The leads 14 b, 14 e are coupled to a drug reservoir/pump 40. - In the
FIG. 6 arrangement, the leads are positionable to deliver drugs to the kidneys, however, the leads may alternatively be positioned elsewhere in the cardiovascular system, including within the heart. In another embodiment, a two-device configuration like that ofFIG. 1C may be used so that electrodes can be positioned in the internal jugular as shown inFIG. 6 as shown, while a separate drug delivery device can be positioned in the aterial system. This allows drug delivery leads 14 b, 14 c to be anchored in the renal arteries, allowing blood flood to propel drugs from the leads to the kidneys. - In the
FIG. 7 embodiment, the neurostimulation device is used to stimulate the central nervous system in order to augment autonomic control of peripheral vascular resistance. The benefits achieved using this embodiment are suitable for treatment of congestive heart failure, as well as hypertension (essential and secondary), diabetes mellitus, and other conditions. - Stimulation may be targeted to one or more of a variety of neurological targets in the brain. In one example shown in
FIG. 7 , stimulating electrodes are positioned in the brain to deliver electrical stimulus that will inhibit the vasomotor center in the rostral ventro-lateral medulla (“RVLM”). The vasomotor center in the RVLM can be inhibited by low-level electrical stimulation to, for example, inhibitory fibers to the nucleus tractus solitarius, and/or stimulation of GABAergic interneurons projecting to the RVLM. For example, an electrode lead can be passed through the subclavian vein and the jugular vein, and then guided to, for example, a superficial cranial vein. Afterwards, the surgeon palpates the skin to find the lead, forms a small incision to gain access to the lead, threads the lead through a treephine hole drilled into the skull, and advances the lead towards the target area within the brain. In some cases the target area may be determined prior to device implantation using direct electrical stimulation of the brain. - Alternatively, the electrical energy may be conducted transvenously through the vessel walls towards the neurological target without penetration of the vessel wall. Access to the neurological target for direct or transvenous stimulation can be gained via veins of the posterior fossa, the petrosal sinus and petrosal veins, the vein of the middle cerebellar peduncle, the lateral medullary and other medullary veins, the retro-olivary vein, regional bridging veins, as well as through other vessels.
- In an alternative embodiment, rather than stimulating the vasomotor center, stimulation may be used to inhibit efferent neurons from the vasomotor center. In this example, stimulation energy can be delivered to any point along the pathway between (and including) the vasomotor center and the prevertebral and paravertebral sympathetic ganglia.
-
FIGS. 8A through 11 illustrate methods for using an intravascular stimulation device for treatment of sleep apnea. The systems used in carrying out these methods preferably deliver stimulation upon receipt of feedback indicative of a cessation in breathing. Various parameters can be sensed for this purpose, including but not limited to: (a) breathing movements using an accelerometer to detect chest movement or a strain gauge to detect chest expansion; (b) changes in lung volume using impedance plethysmography to measure transthoracic impedance changes; (c) changes in breathing efficiency using an intravascular chemical sensor for detecting blood CO2 or O2 concentrations; (d) sleep state using EEG electrodes positioned on the scalp or within the brain; (e) facial movements, especially rapid eye movement, using an accelerometer; (f) snoring using acoustic detection methods; (g) muscle tone of specific throat structures using electrodes; (g) changes in airway flow rates and pressures to monitor airway patency. - The
FIG. 8A embodiment uses phrenic nerve stimulation as a means for treating sleep apnea. For example, in response to detection of a threshold CO2 level by aCO2 sensor 60 positioned on thedevice 12 or lead 14, one or more stimulating pulses are delivered to the phrenic nerve, causing contraction of the diaphragm to expand the lungs and to thus draw air into the lungs. Similar device positioning might also be used for diaphragmatic pacing to facilitate breathing in patients having neurological injuries or disorders, such as motor neuron disease and spinal cord injury, among others. Devices for diaphragmatic pacing might include features allowing for rate adaptive breathing rate modulation, allowing pacing to be responsive to feedback from one or more sensors indicating various metabolic needs. Suitable sensors include, for example, accelerometers for detecting patient motion, heart rate monitors, and pCO2 and pO2 sensors. - In the illustrated embodiment, electrodes are anchored in the left and right subclavian veins, near the phrenic nerves. According to one electrode positioning method shown in
FIG. 8B , electrodes may be positioned directly in contact with the phrenic nerve by extending anelectrode lead 14 through an opening O formed in a wall of a blood vessel, preferably at a location near the phrenic nerve. A vascular sealing member orsubstance 62 may be used to close the opening O in the region surrounding the lead to minimize bleeding. The lead is positioned in contact with the phrenic nerve, or embedded within the nerve tissue, such that by energizing the electrode the nerve may be directly stimulated. - Alternatively, as shown in
FIG. 8C , the lead may be positioned within an intact vessel (e.g. a subclavian vein) at a point at which the vessel crosses the phrenic nerve, thus allowing conduction of the electrical stimuli from the electrode through the vessel to the phrenic nerve. -
FIG. 9 shows an alternative electrode arrangement suitable for treating sleep apnea. According to this embodiment, electrodes are positioned such that stimulation energy passes transvenously through the walls of blood vessels that are in electrical contact with the diaphragm, thus stimulating the diaphragm. Electrodes may be positioned in the right and left hepatic veins as shown, or in any other sites including but not limited to the inferior vena cava. As with theFIG. 8A embodiment, this embodiment is also suitable as a diaphragmatic pacer to facilitate breathing in patients having motor neuron disease, spinal cord injury, or other diseases/conditions. - In the
FIG. 10 embodiment, electrical stimulation is delivered to the hypoglossal nerve, which innervates the muscles of the tongue. This embodiment may be useful for treating obstructive sleep apnea in a patient whose tongue relaxes during sleep to a point at which the tongue causes an obstruction of the airways. Stimulating the hypoglossal nerve can increase the tone of the muscles of the tongue, thus opening the airways. - In one exemplary electrode position shown in
FIG. 10 , energy is conducted to the hypoglossal nerve using electrddes anchored in the left and right internal jugular veins, near the points where those veins cross the left and right hypoglossal nerves. If the oropharyngeal muscles are instrumental in obstructing the airway during sleep, the electrodes may be positioned to stimulate the oropharyngeal muscles or the nerves that innervate them, so as to contract those muscles away from the airway. - In another treatment which may be used for sleep apnea or other conditions for which deep brain stimulation is suitable (e.g. epilepsy), lead 14 may be extended into the brain (for example, as described in connection with
FIG. 7 ) for deep brain stimulation as shown inFIG. 11A . Routes for passage of the lead into the brain include, but are not limited to, the facial vein and the retro-mandibular vein.FIG. 11B illustrates positioning of thedevice 12 in the inferior vena cava, with thelead 14 extending superiorly towards the brain. - The disclosed system may be used to deliver vagus nerve stimulation for treatment of various diseases or conditions, including but not limited to epilepsy, depression, Alzheimer's disease, anxiety disorders (for example, obsessive compulsive disorder), tourette syndrome, bulimia, and obesity. The
FIG. 12 embodiment illustrates positioning of stimulation electrodes in the internal jugular vein at a location from which energy from the electrodes can be conducted through the jugular vein to the left vagus nerve. Alternate electrode positions might also be used, including the superior vena cava and the brachio-cephalic veins, among others. AlthoughFIG. 12 illustrates transvenous stimulation of the nerve, it should be appreciated that with any of the disclosed embodiments, direct stimulation may instead be employed by passing the lead through the vessel wall and positioning it in contact with the target neural structure. - Neurostimulation of cardiac parasympathetic nerves and plexuses may be used to treat multiple types of aberrant heart rates and rhythms. In one example shown in
FIG. 13 , of a neurostimulation system is used for ventricular rate control during atrial fibrillation. In this embodiment, the electrode is positioned within the superior vena cava or in an alternate location from which it can be used to stimulate adjacent cardiac parasympathetic nerves to achieve ventricular rate control during atrial fibrillation. Operating parameters may be selected to deliver high-frequency (e.g. on the order of 50-250 Hz) nerve stimuli during the atrial refractory period, thus preventing atrial excitation during the adjacent nerve stimulation. - Neurostimulation of cardiac parasympathetic nerves and plexuses may be accomplished either directly or transvenously, and may be performed at multiple sites, including but not limited to the superior vena cava, the inferior vena cava, and the coronary sinus.
- Alternative Applications
- Suitable applications for use of these devices/systems include, but are not limited to:
- Deep brain stimulation (DBS) or cortical stimulation (alone or in combination with drug delivery to the stimulated area) for treatment of motor disorders including essential tremor, Parkinson's disease, Dystonia, for stroke rehabilitation, as well as other neurological disorders including obsessive conpulsive disorder. epilepsy, depression, mood disorders, anxiety disorders, pain and tinnitus. Stimulation might be delivered to regions of the brain (e.g. the insula) to control addiction to substances or behavior.
- Occipital nerve stimulation (ONS) for treatment of headaches;
- Vagus nerve stimulation (VNS) for treatment of epilepsy, depression, hypertension or heart failure;
- Peripheral nerve stimulation (PNS) for treatment of chronic pain;
- Spinal cord stimulation (SCS) (alone or in combination with drug delivery to the stimulated area) for treatment of chronic pain, angina pain, peripheral vascular disease pain, malignant pain, ALS symptoms, and symptoms of Huntington's disease;
- Stimulation of nerves in the gastric system for obesity treatment and gastroparesis;
- Sacral or pelvic nerve stimulation for treatment of incontinence, pelvic pain, and sexual dysfunction;
- Stimulation of the pancreas to upregulate the production of insulin or the electroporation of islet cells in treatment of diabetes.
- The devices disclosed might be used for non-neurological therapy as well, such as the use of internal electrical stimulus to promote healing of wounds on or within the body. For example, targeted sympathetic blockade or parasympathetic nerve stimulation may be used to increase regional blood flow in various target areas to promote ulcer healing in patients with peripheral vascular disease.
- While various embodiments of the present invention have been described above, it should be understood that they have been presented by way of example, and not limitation. It will be apparent to persons skilled in the relevant art that various changes in tbrm and detail may be made therein without departing from the spirit and scope of the invention. This is especially true in light of technology and terms within the relevant art(s) that may be later developed. Thus, the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents. The terms “first,” “second” and the like, where used herein, do not denote any order, quantity, or importance. In references to “first blood vessel”, “second blood vessel” etc., the first and second blood vessels may be different blood vessels or they may be the same blood vessel unless otherwise specified.
- Any and all patents, patent applications and printed publications referred to above are incorporated by reference.
Claims (29)
1. A method of electrically modulating a nervous system target, comprising the steps of:
introducing a neuromodulation implant into the vasculature of a patient, the neuromodulation implant including a device body and a pulse generator within the device body;
positioning at least one electrode within a superior vena cava of the patient, the electrode in communication with the device body,
chronically retaining the neuromodulation implant within the vasculature; and
with the electrode in the superior vena cava, stimulating the nervous system target using the electrode.
2. The method of claim 1 , wherein chronically retaining the neuromodulation implant retains the electrode in the superior vena cava.
3. The method of claim 2 , wherein, when the neuromodulation implant is chronically retained, the device body is disposed in an inferior vena cava and the electrode is disposed in the superior vena cava.
4. The method according to claim 1 , wherein the electrode is on a lead, and wherein the method further includes passing the lead and electrode into the superior vena cava to position the electrode.
5. The method according to claim 4 , further including anchoring the lead within the superior vena cava.
6. The method according to claim 1 , wherein the nervous system target includes a parasympathetic nervous system target.
7. The method according to claim 1 , wherein the nervous system target includes a sympathetic nervous system target.
8. The method according to according to claim 1 , wherein stimulating the nervous system target includes stimulating a cardiac parasympathetic nerve target to treat atrial fibrillation.
9. The method according to claim 1 , wherein stimulating the nervous system target includes stimulating the vagus nerve to treat heart failure.
10. The method of claim 1 , wherein retaining the implant includes expanding an anchor into contact within the wall of the superior vena cava, the anchor retaining the implant.
11. The method according to claim 1 , wherein the neuromodulation implant includes a power source, and wherein the method further includes wirelessly recharging the power source using an external charging device.
12. The method according to claim 11 , wherein the external charging device recharges the power source using inductive coupling.
13. The method according to claim 11 , wherein the external charging device recharges the power source using an optical energy source impinging radiant energy through the body to a photovoltaic cell electrically connected to the power source.
14. The method according to claim 11 , wherein the external charging device recharges the power source using a mechanical energy source impinging vibrational energy through the body to a piezoelectric element electrically connected to the power source.
15. A neuromodulation system comprising:
a neuromodulation implant including an intravascular pulse generator;
an anchor engageable with a wall of a superior vena cava to anchor the neuromodulation implant within the vasculature; and
at least one electrode carried by the anchor, wherein engagement of the blood vessel wall by the anchor positions the electrode in contact the superior vena cava wall proximate to a nervous system target.
16. The system according to claim 15 , further including a lead extending between the pulse generator and the anchor, wherein the anchor is on the lead.
17. The system according to claim 16 , including a plurality of electrodes on the anchor.
18. The system according to claim 15 , wherein the anchor is a member radially expandable into contact with a blood vessel wall, wherein the electrode is on the radially expandable member.
19. The system according to claim 18 , further including a plurality of electrically isolated electrodes on the member.
20. The system according to claim 15 , wherein the neurostimulation implant is proportioned such that the pulse generator is disposed in an inferior vena cava when the anchor is engaged with the superior vena cava.
21. The system according to claim 15 , wherein the system includes a sensor device positioned to detect a body condition, the implant configured to deliver one or more neuromodulation pulses at the electrode in response to feedback from the sensor device.
22. The system according to claim 21 , wherein the sensor device is on the implant.
23. The system according to claim 22 , wherein the sensor device is coupled to the implant and positionable at a location in the body remote from the anchoring location.
24. The system according to claim 21 , wherein the sensor device is in wireless communication with the implant.
25. The system according to claim 21 , wherein the sensor device is an extracorporeal sensor.
26. The system according to claim 21 , wherein the sensor is configured for implantation with the body of the patient.
27. The system of claim 15 , wherein the implant includes a rechargeable power source, and wherein the system further includes an external charging device positionable to inductively couple energy to the rechargeable power source.
28. The system according to claim 15 , further including a second anchor expandable to anchor a portion of the implant within a second blood vessel.
29. The system according to claim 28 , wherein the second blood vessel is the inferior vena cava.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/294,140 US20120059431A1 (en) | 2006-02-03 | 2011-11-10 | Intravascular Device for Neuromodulation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76542006P | 2006-02-03 | 2006-02-03 | |
US11/702,000 US8116883B2 (en) | 2003-06-04 | 2007-02-02 | Intravascular device for neuromodulation |
US13/294,140 US20120059431A1 (en) | 2006-02-03 | 2011-11-10 | Intravascular Device for Neuromodulation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/702,000 Continuation US8116883B2 (en) | 2003-06-04 | 2007-02-02 | Intravascular device for neuromodulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120059431A1 true US20120059431A1 (en) | 2012-03-08 |
Family
ID=38179674
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/702,000 Expired - Fee Related US8116883B2 (en) | 2003-06-04 | 2007-02-02 | Intravascular device for neuromodulation |
US13/294,140 Abandoned US20120059431A1 (en) | 2006-02-03 | 2011-11-10 | Intravascular Device for Neuromodulation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/702,000 Expired - Fee Related US8116883B2 (en) | 2003-06-04 | 2007-02-02 | Intravascular device for neuromodulation |
Country Status (6)
Country | Link |
---|---|
US (2) | US8116883B2 (en) |
EP (1) | EP1981584B1 (en) |
JP (1) | JP5256048B2 (en) |
AU (1) | AU2007212587B2 (en) |
CA (1) | CA2637787A1 (en) |
WO (1) | WO2007092330A1 (en) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080281365A1 (en) * | 2007-05-09 | 2008-11-13 | Tweden Katherine S | Neural signal duty cycle |
US20090210019A1 (en) * | 2008-02-14 | 2009-08-20 | Dennis Dong-Won Kim | Treatment of excess weight by neural downregulation in combination with compositions |
US20100130892A1 (en) * | 2006-05-19 | 2010-05-27 | Prorhythm, In. | Ablation device with optimized input power profile and method of using the same |
US20110118632A1 (en) * | 2003-02-20 | 2011-05-19 | Recor Medical, Inc. | Cardiac ablation devices |
US8521299B2 (en) | 2007-03-09 | 2013-08-27 | Enteromedics Inc. | Remote monitoring and control of implantable devices |
US8532787B2 (en) | 2007-05-31 | 2013-09-10 | Enteromedics Inc. | Implantable therapy system having multiple operating modes |
US8538542B2 (en) | 2003-02-03 | 2013-09-17 | Enteromedics Inc. | Nerve stimulation and blocking for treatment of gastrointestinal disorders |
US8538533B2 (en) | 2003-02-03 | 2013-09-17 | Enteromedics Inc. | Controlled vagal blockage therapy |
US8594806B2 (en) | 2010-04-30 | 2013-11-26 | Cyberonics, Inc. | Recharging and communication lead for an implantable device |
US8768469B2 (en) | 2008-08-08 | 2014-07-01 | Enteromedics Inc. | Systems for regulation of blood pressure and heart rate |
US8825164B2 (en) | 2010-06-11 | 2014-09-02 | Enteromedics Inc. | Neural modulation devices and methods |
US20140277253A1 (en) * | 2013-03-15 | 2014-09-18 | Boston Scientific Neuromodulation Corporation | Neuromodulation of renal nerve for treatment of hypertension |
US8862233B2 (en) | 2003-02-03 | 2014-10-14 | Enteromedics Inc. | Electrode band system and methods of using the system to treat obesity |
US8974445B2 (en) | 2009-01-09 | 2015-03-10 | Recor Medical, Inc. | Methods and apparatus for treatment of cardiac valve insufficiency |
US9289612B1 (en) | 2014-12-11 | 2016-03-22 | Medtronic Inc. | Coordination of ventricular pacing in a leadless pacing system |
US9333340B2 (en) | 2008-04-04 | 2016-05-10 | Enteromedics Inc. | Methods and systems for glucose regulation |
US9393420B2 (en) | 2012-03-09 | 2016-07-19 | Enteromedics Inc. | Safety features for use in medical devices |
US9399140B2 (en) | 2014-07-25 | 2016-07-26 | Medtronic, Inc. | Atrial contraction detection by a ventricular leadless pacing device for atrio-synchronous ventricular pacing |
US9492668B2 (en) | 2014-11-11 | 2016-11-15 | Medtronic, Inc. | Mode switching by a ventricular leadless pacing device |
US9492669B2 (en) | 2014-11-11 | 2016-11-15 | Medtronic, Inc. | Mode switching by a ventricular leadless pacing device |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US9623234B2 (en) | 2014-11-11 | 2017-04-18 | Medtronic, Inc. | Leadless pacing device implantation |
US9724519B2 (en) | 2014-11-11 | 2017-08-08 | Medtronic, Inc. | Ventricular leadless pacing device mode switching |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10390720B2 (en) | 2014-07-17 | 2019-08-27 | Medtronic, Inc. | Leadless pacing system including sensing extension |
US10413436B2 (en) | 2010-06-13 | 2019-09-17 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US11207527B2 (en) | 2016-07-06 | 2021-12-28 | Cardiac Pacemakers, Inc. | Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
EP3905993A4 (en) * | 2019-01-02 | 2022-10-12 | Shifamed Holdings, LLC | Multi-transmitter sensor system |
US11633194B2 (en) | 2020-11-12 | 2023-04-25 | Shifamed Holdings, Llc | Adjustable implantable devices and associated methods |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11801369B2 (en) | 2020-08-25 | 2023-10-31 | Shifamed Holdings, Llc | Adjustable interatrial shunts and associated systems and methods |
Families Citing this family (238)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7493171B1 (en) * | 2000-11-21 | 2009-02-17 | Boston Scientific Neuromodulation Corp. | Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion |
US7837719B2 (en) | 2002-05-09 | 2010-11-23 | Daemen College | Electrical stimulation unit and waterbath system |
US20040082859A1 (en) | 2002-07-01 | 2004-04-29 | Alan Schaer | Method and apparatus employing ultrasound energy to treat body sphincters |
DE202004021942U1 (en) | 2003-09-12 | 2013-05-13 | Vessix Vascular, Inc. | Selectable eccentric remodeling and / or ablation of atherosclerotic material |
US8396548B2 (en) | 2008-11-14 | 2013-03-12 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
US9125667B2 (en) | 2004-09-10 | 2015-09-08 | Vessix Vascular, Inc. | System for inducing desirable temperature effects on body tissue |
US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
US7499748B2 (en) * | 2005-04-11 | 2009-03-03 | Cardiac Pacemakers, Inc. | Transvascular neural stimulation device |
US7734348B2 (en) | 2005-05-10 | 2010-06-08 | Cardiac Pacemakers, Inc. | System with left/right pulmonary artery electrodes |
US8862243B2 (en) | 2005-07-25 | 2014-10-14 | Rainbow Medical Ltd. | Electrical stimulation of blood vessels |
WO2007098200A2 (en) | 2006-02-16 | 2007-08-30 | Imthera Medical, Inc. | An rfid-based apparatus, system, and method for therapeutic treatment of obstructive sleep apnea |
US8019435B2 (en) | 2006-05-02 | 2011-09-13 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
US7734341B2 (en) * | 2006-06-06 | 2010-06-08 | Cardiac Pacemakers, Inc. | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US20070282376A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and apparatus for neural stimulation via the lymphatic system |
US8905999B2 (en) * | 2006-09-01 | 2014-12-09 | Cardiac Pacemakers, Inc. | Method and apparatus for endolymphatic drug delivery |
AU2007310986B2 (en) | 2006-10-18 | 2013-07-04 | Boston Scientific Scimed, Inc. | Inducing desirable temperature effects on body tissue |
AU2007310988B2 (en) | 2006-10-18 | 2013-08-15 | Vessix Vascular, Inc. | Tuned RF energy and electrical tissue characterization for selective treatment of target tissues |
US8579853B2 (en) * | 2006-10-31 | 2013-11-12 | Abbott Diabetes Care Inc. | Infusion devices and methods |
EP2094352A4 (en) | 2006-12-06 | 2010-05-19 | Cleveland Clinic Foundation | Method and system for treating acute heart failure by neuromodulation |
EP2121124A1 (en) * | 2006-12-15 | 2009-11-25 | Nasophlex B.V. | Resuscitation device and method for resuscitation |
CA2676119C (en) | 2007-01-29 | 2021-01-19 | Simon Fraser University | Transvascular nerve stimulation apparatus and methods |
US8209033B2 (en) * | 2007-05-14 | 2012-06-26 | Cardiac Pacemakers, Inc. | Method and apparatus for regulating blood volume using volume receptor stimulation |
US20080294228A1 (en) * | 2007-05-23 | 2008-11-27 | Cardiac Pacemakers | Method and device for controlled stimulation of lymphatic flow |
US8983609B2 (en) | 2007-05-30 | 2015-03-17 | The Cleveland Clinic Foundation | Apparatus and method for treating pulmonary conditions |
CA2697826A1 (en) | 2007-10-09 | 2009-04-16 | Imthera Medical, Inc. | System and method for neural stimulation |
US9008782B2 (en) * | 2007-10-26 | 2015-04-14 | Medtronic, Inc. | Occipital nerve stimulation |
JP5189654B2 (en) | 2007-12-12 | 2013-04-24 | カーディアック ペースメイカーズ, インコーポレイテッド | A stimulation system that transmits neural stimulation from the pulmonary artery |
US8155744B2 (en) | 2007-12-13 | 2012-04-10 | The Cleveland Clinic Foundation | Neuromodulatory methods for treating pulmonary disorders |
US8538535B2 (en) | 2010-08-05 | 2013-09-17 | Rainbow Medical Ltd. | Enhancing perfusion by contraction |
US7925352B2 (en) | 2008-03-27 | 2011-04-12 | Synecor Llc | System and method for transvascularly stimulating contents of the carotid sheath |
US8340785B2 (en) * | 2008-05-02 | 2012-12-25 | Medtronic, Inc. | Self expanding electrode cuff |
CN102112177A (en) * | 2008-05-02 | 2011-06-29 | 梅德特龙尼克有限公司 | Self expanding electrode cuff |
NL2001695C2 (en) * | 2008-06-18 | 2009-12-22 | Kerphos B V | Implantable electronic system useful for producing stimulation signal to human, has controller for processing parameter values to generate control signal for stimulation device based on detected parameter values |
NL2001697C2 (en) | 2008-06-18 | 2009-12-22 | Nasophlex B V | Nose stimulator for producing a stimulation signal to a nose. |
NL2001698C2 (en) | 2008-06-18 | 2009-12-22 | Nasophlex B V | Cardioverter / defibrillator. |
NL2001694C2 (en) * | 2008-06-18 | 2009-12-22 | Nasophlex B V | Ear stimulator for producing a stimulation signal to an ear. |
US20100171394A1 (en) * | 2008-07-06 | 2010-07-08 | Glenn Richard A | Energy harvesting for implanted medical devices |
US8239037B2 (en) * | 2008-07-06 | 2012-08-07 | Synecor Llc | Intravascular implant anchors having remote communication and/or battery recharging capabilities |
EP3536376A1 (en) | 2008-07-30 | 2019-09-11 | Ecole Polytechnique Fédérale de Lausanne | Apparatus for optimized stimulation of a neurological target |
US20100030227A1 (en) * | 2008-07-31 | 2010-02-04 | Medtronic, Inc. | Medical lead implantation |
WO2010019481A1 (en) | 2008-08-11 | 2010-02-18 | Conceptx Medical, Inc. | Systems and methods for treating dyspnea, including via electrical afferent signal blocking |
US20100042185A1 (en) * | 2008-08-12 | 2010-02-18 | Curtis Guy P | System and method for transvascular activation of cardiac nerves to improve heart function |
US8463376B2 (en) | 2008-08-12 | 2013-06-11 | Guy P. Curtis | System and method for transvascular activation of cardiac nerves with automatic restart |
EP3714771A1 (en) * | 2008-10-01 | 2020-09-30 | Inspire Medical Systems, Inc. | System for treating sleep apnea transvenously |
US8359107B2 (en) | 2008-10-09 | 2013-01-22 | Boston Scientific Neuromodulation Corporation | Electrode design for leads of implantable electric stimulation systems and methods of making and using |
CA2738479C (en) | 2008-10-09 | 2017-11-28 | Imthera Medical, Inc. | Method of stimulating a hypoglossal nerve for controlling the position of a patient's tongue |
JP5667987B2 (en) | 2008-11-12 | 2015-02-12 | エコーレ ポリテクニーク フェデラーレ デ ローザンヌ (イーピーエフエル) | Micromachined nerve stimulation device |
AU2009314133B2 (en) | 2008-11-17 | 2015-12-10 | Vessix Vascular, Inc. | Selective accumulation of energy with or without knowledge of tissue topography |
JP5575789B2 (en) | 2008-11-19 | 2014-08-20 | インスパイア・メディカル・システムズ・インコーポレイテッド | How to treat sleep-disordered breathing |
US8515520B2 (en) | 2008-12-08 | 2013-08-20 | Medtronic Xomed, Inc. | Nerve electrode |
JP2012521864A (en) | 2009-03-31 | 2012-09-20 | インスパイア・メディカル・システムズ・インコーポレイテッド | Percutaneous access method in a system for treating sleep-related abnormal breathing |
US8715327B1 (en) | 2009-04-13 | 2014-05-06 | Cvrx, Inc. | Baroreflex modulation using light-based stimulation |
US20100298720A1 (en) * | 2009-04-16 | 2010-11-25 | Potkay Joseph Allen | In Situ Energy Harvesting Systems for Implanted Medical Devices |
WO2010131219A1 (en) * | 2009-05-14 | 2010-11-18 | Samson Neurosciences Ltd. | Endovascular electrostimulation near a carotid bifurcation in treating cerebrovascular conditions |
US8412349B2 (en) * | 2009-06-04 | 2013-04-02 | Boston Scientific Neuromodulation Corporation | Three-piece button anchor and methods and devices using the anchor |
WO2010148411A1 (en) * | 2009-06-19 | 2010-12-23 | Entelos, Inc. | Method and apparatus for computer modeling hypertension |
US9468755B2 (en) * | 2009-09-30 | 2016-10-18 | Respicardia, Inc. | Medical lead with preformed bias |
US20110093026A1 (en) * | 2009-10-19 | 2011-04-21 | Ramesh Wariar | Method and apparatus for cardiorenal electrical stimulation |
US9409013B2 (en) | 2009-10-20 | 2016-08-09 | Nyxoah SA | Method for controlling energy delivery as a function of degree of coupling |
US9415215B2 (en) | 2009-10-20 | 2016-08-16 | Nyxoah SA | Methods for treatment of sleep apnea |
BR112012010986A2 (en) | 2009-11-10 | 2016-04-12 | Imthera Medical Inc | system to stimulate a hypoglossal nerve to control a patient's tongue position |
JP2013512062A (en) | 2009-12-01 | 2013-04-11 | エコーレ ポリテクニーク フェデラーレ デ ローザンヌ | Microfabricated surface nerve stimulation device and methods of making and using the same |
WO2011074339A1 (en) * | 2009-12-14 | 2011-06-23 | テルモ株式会社 | Electric stimulation device |
US8825129B2 (en) * | 2010-03-05 | 2014-09-02 | Sri International | Indwelling nerve block catheters |
WO2011112843A1 (en) | 2010-03-12 | 2011-09-15 | Inspire Medical Systems, Inc. | Method and system for identifying a location for nerve stimulation |
US9549708B2 (en) | 2010-04-01 | 2017-01-24 | Ecole Polytechnique Federale De Lausanne | Device for interacting with neurological tissue and methods of making and using the same |
KR20130108067A (en) | 2010-04-09 | 2013-10-02 | 베식스 바스큘라 인코포레이티드 | Power generating and control apparatus for the treatment of tissue |
US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
US8602996B2 (en) | 2010-06-01 | 2013-12-10 | Cardiac Pacemakers, Inc. | Integrating device-based sensors and bedside biomarker assays to detect worsening heart failure |
EP2579809B1 (en) | 2010-06-08 | 2020-11-25 | Regents of the University of Minnesota | Vascular elastance |
US8473067B2 (en) | 2010-06-11 | 2013-06-25 | Boston Scientific Scimed, Inc. | Renal denervation and stimulation employing wireless vascular energy transfer arrangement |
US9155589B2 (en) | 2010-07-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Sequential activation RF electrode set for renal nerve ablation |
US9463062B2 (en) | 2010-07-30 | 2016-10-11 | Boston Scientific Scimed, Inc. | Cooled conductive balloon RF catheter for renal nerve ablation |
US9084609B2 (en) | 2010-07-30 | 2015-07-21 | Boston Scientific Scime, Inc. | Spiral balloon catheter for renal nerve ablation |
US9358365B2 (en) | 2010-07-30 | 2016-06-07 | Boston Scientific Scimed, Inc. | Precision electrode movement control for renal nerve ablation |
US9408661B2 (en) | 2010-07-30 | 2016-08-09 | Patrick A. Haverkost | RF electrodes on multiple flexible wires for renal nerve ablation |
WO2012030393A1 (en) * | 2010-08-31 | 2012-03-08 | Synecor Llc | Intravascular electrodes and anchoring devices for transvascular stimulation |
US8934956B2 (en) * | 2010-08-31 | 2015-01-13 | Interventional Autonomics Corporation | Intravascular electrodes and anchoring devices for transvascular stimulation |
US8974451B2 (en) | 2010-10-25 | 2015-03-10 | Boston Scientific Scimed, Inc. | Renal nerve ablation using conductive fluid jet and RF energy |
US9220558B2 (en) | 2010-10-27 | 2015-12-29 | Boston Scientific Scimed, Inc. | RF renal denervation catheter with multiple independent electrodes |
US9028485B2 (en) | 2010-11-15 | 2015-05-12 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
US9457186B2 (en) * | 2010-11-15 | 2016-10-04 | Bluewind Medical Ltd. | Bilateral feedback |
US9089350B2 (en) | 2010-11-16 | 2015-07-28 | Boston Scientific Scimed, Inc. | Renal denervation catheter with RF electrode and integral contrast dye injection arrangement |
US9668811B2 (en) | 2010-11-16 | 2017-06-06 | Boston Scientific Scimed, Inc. | Minimally invasive access for renal nerve ablation |
US9326751B2 (en) | 2010-11-17 | 2016-05-03 | Boston Scientific Scimed, Inc. | Catheter guidance of external energy for renal denervation |
US9060761B2 (en) | 2010-11-18 | 2015-06-23 | Boston Scientific Scime, Inc. | Catheter-focused magnetic field induced renal nerve ablation |
US9192435B2 (en) | 2010-11-22 | 2015-11-24 | Boston Scientific Scimed, Inc. | Renal denervation catheter with cooled RF electrode |
JP5782523B2 (en) | 2010-11-22 | 2015-09-24 | アリア シーブイ, インコーポレイテッド | System and method for reducing pulsating pressure |
US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
US20120157993A1 (en) | 2010-12-15 | 2012-06-21 | Jenson Mark L | Bipolar Off-Wall Electrode Device for Renal Nerve Ablation |
CA2822079A1 (en) * | 2010-12-17 | 2012-06-21 | Neural Diabetes Llc | Method, system and apparatus for control of pancreatic beta cell function to improve glucose homeostatis and insulin production |
US20120158086A1 (en) * | 2010-12-17 | 2012-06-21 | Medtronic, Inc. | Aortic pacing to reduce heart rate |
WO2012100095A1 (en) | 2011-01-19 | 2012-07-26 | Boston Scientific Scimed, Inc. | Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury |
US20120253422A1 (en) * | 2011-03-30 | 2012-10-04 | Nevro Corporation | Systems and methods for selecting neural modulation contacts from among multiple contacts |
EP2701795B1 (en) | 2011-04-28 | 2020-12-09 | Interventional Autonomics Corporation | Neuromodulation systems for treating acute heart failure syndromes |
US8489205B2 (en) * | 2011-05-03 | 2013-07-16 | Biotronik Se & Co. Kg | System for temporary fixation of an implantable medical device |
US20130072995A1 (en) * | 2011-07-11 | 2013-03-21 | Terrance Ransbury | Catheter system for acute neuromodulation |
AU2012299373A1 (en) * | 2011-07-11 | 2014-02-27 | Interventional Autonomics Corporation | System and method for neuromodulation |
EP2701790B1 (en) * | 2011-07-11 | 2016-04-20 | Interventional Autonomics Corporation | Intravascular electrodes and anchoring devices for transvascular stimulation |
CN103813745B (en) | 2011-07-20 | 2016-06-29 | 波士顿科学西美德公司 | In order to visualize, be directed at and to melt transcutaneous device and the method for nerve |
JP6106669B2 (en) | 2011-07-22 | 2017-04-05 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | A neuromodulation system having a neuromodulation element that can be placed in a helical guide |
US8706235B2 (en) | 2011-07-27 | 2014-04-22 | Medtronic, Inc. | Transvenous method to induce respiration |
JP2014522713A (en) * | 2011-08-10 | 2014-09-08 | カーディアック ペースメイカーズ, インコーポレイテッド | Determination of physiological parameters using cervical impedance |
WO2013023218A1 (en) | 2011-08-11 | 2013-02-14 | Inspire Medical Systems, Inc. | System for selecting a stimulation protocol based on sensed respiratory effort |
US8702619B2 (en) | 2011-08-26 | 2014-04-22 | Symap Holding Limited | Mapping sympathetic nerve distribution for renal ablation and catheters for same |
US9820811B2 (en) | 2011-08-26 | 2017-11-21 | Symap Medical (Suzhou), Ltd | System and method for mapping the functional nerves innervating the wall of arteries, 3-D mapping and catheters for same |
EP3659537B1 (en) | 2011-08-26 | 2023-12-06 | Symap Medical (Suzhou) Ltd | System for locating and identifying functional nerves innervating wall of arteries |
US20130231725A1 (en) * | 2011-08-30 | 2013-09-05 | Michael Williams | Peripheral Afferent Nerve Stimulation for Treatment of Epilepsy |
US8934992B2 (en) | 2011-09-01 | 2015-01-13 | Inspire Medical Systems, Inc. | Nerve cuff |
WO2013035092A2 (en) | 2011-09-09 | 2013-03-14 | Enopace Biomedical Ltd. | Wireless endovascular stent-based electrodes |
BR112014007612A2 (en) | 2011-09-30 | 2017-04-25 | Nyxoah SA | modulated appliance configured for deployment |
WO2013055826A1 (en) | 2011-10-10 | 2013-04-18 | Boston Scientific Scimed, Inc. | Medical devices including ablation electrodes |
US10085799B2 (en) | 2011-10-11 | 2018-10-02 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
US9420955B2 (en) | 2011-10-11 | 2016-08-23 | Boston Scientific Scimed, Inc. | Intravascular temperature monitoring system and method |
US9364284B2 (en) | 2011-10-12 | 2016-06-14 | Boston Scientific Scimed, Inc. | Method of making an off-wall spacer cage |
EP2768568B1 (en) | 2011-10-18 | 2020-05-06 | Boston Scientific Scimed, Inc. | Integrated crossing balloon catheter |
WO2013058962A1 (en) | 2011-10-18 | 2013-04-25 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
EP2775948B1 (en) | 2011-11-08 | 2018-04-04 | Boston Scientific Scimed, Inc. | Ostial renal nerve ablation |
US9119600B2 (en) | 2011-11-15 | 2015-09-01 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
US9119632B2 (en) | 2011-11-21 | 2015-09-01 | Boston Scientific Scimed, Inc. | Deflectable renal nerve ablation catheter |
WO2013090848A1 (en) | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and methods for treating pulmonary hypertension |
US9265969B2 (en) | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
WO2013096916A2 (en) | 2011-12-23 | 2013-06-27 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9433760B2 (en) | 2011-12-28 | 2016-09-06 | Boston Scientific Scimed, Inc. | Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements |
US9050106B2 (en) | 2011-12-29 | 2015-06-09 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
US8958890B2 (en) | 2012-01-17 | 2015-02-17 | Neuronexus Technologies, Inc. | Implantable neural interface device with a deformable carrier |
WO2013116544A1 (en) | 2012-01-31 | 2013-08-08 | Cardiac Pacemakers, Inc. | Systems and methods for controlling a cardiac resynchronisation device/therapy using biomarker panel data |
CN107126622A (en) * | 2012-03-05 | 2017-09-05 | 西蒙·弗雷瑟大学 | neural stimulation system |
WO2013134479A1 (en) * | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg Sarl | Neuromodulation and associated systems and methods for the management of pain |
US8903509B2 (en) * | 2012-03-21 | 2014-12-02 | Cardiac Pacemakers Inc. | Systems and methods for stimulation of vagus nerve |
EP2840993A4 (en) | 2012-04-24 | 2016-03-30 | Cibiem Inc | Endovascular catheters and methods for carotid body ablation |
US10660703B2 (en) | 2012-05-08 | 2020-05-26 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices |
EP2854681A4 (en) | 2012-06-01 | 2016-02-17 | Cibiem Inc | Percutaneous methods and devices for carotid body ablation |
US9402677B2 (en) | 2012-06-01 | 2016-08-02 | Cibiem, Inc. | Methods and devices for cryogenic carotid body ablation |
BR112014032002A2 (en) | 2012-06-21 | 2017-06-27 | Univ Fraser Simon | transvascular diaphragm stimulation systems and methods of use |
WO2014005155A1 (en) | 2012-06-30 | 2014-01-03 | Cibiem, Inc. | Carotid body ablation via directed energy |
JP6085429B2 (en) * | 2012-07-19 | 2017-02-22 | 株式会社 東北テクノアーチ | Surface-type vagus nerve electrical stimulation device with cardiac function monitoring device |
US10321946B2 (en) | 2012-08-24 | 2019-06-18 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices with weeping RF ablation balloons |
US9173696B2 (en) | 2012-09-17 | 2015-11-03 | Boston Scientific Scimed, Inc. | Self-positioning electrode system and method for renal nerve modulation |
US10549127B2 (en) | 2012-09-21 | 2020-02-04 | Boston Scientific Scimed, Inc. | Self-cooling ultrasound ablation catheter |
US10398464B2 (en) | 2012-09-21 | 2019-09-03 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
CN104869930B (en) | 2012-10-10 | 2020-12-25 | 波士顿科学国际有限公司 | Renal neuromodulation apparatus and methods |
CN102908191A (en) | 2012-11-13 | 2013-02-06 | 陈绍良 | Multipolar synchronous pulmonary artery radiofrequency ablation catheter |
US9827036B2 (en) | 2012-11-13 | 2017-11-28 | Pulnovo Medical (Wuxi) Co., Ltd. | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
US11241267B2 (en) | 2012-11-13 | 2022-02-08 | Pulnovo Medical (Wuxi) Co., Ltd | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
US9693821B2 (en) | 2013-03-11 | 2017-07-04 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9956033B2 (en) | 2013-03-11 | 2018-05-01 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9808311B2 (en) | 2013-03-13 | 2017-11-07 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
EP2967734B1 (en) | 2013-03-15 | 2019-05-15 | Boston Scientific Scimed, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
US9297845B2 (en) | 2013-03-15 | 2016-03-29 | Boston Scientific Scimed, Inc. | Medical devices and methods for treatment of hypertension that utilize impedance compensation |
EP2813263A1 (en) * | 2013-06-12 | 2014-12-17 | Achim Gutersohn | Pacemaker system with a holding device |
EP3010437A1 (en) | 2013-06-21 | 2016-04-27 | Boston Scientific Scimed, Inc. | Renal denervation balloon catheter with ride along electrode support |
CN105473092B (en) | 2013-06-21 | 2019-05-17 | 波士顿科学国际有限公司 | The medical instrument for renal nerve ablation with rotatable shaft |
US9707036B2 (en) | 2013-06-25 | 2017-07-18 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation using localized indifferent electrodes |
WO2015002787A1 (en) | 2013-07-01 | 2015-01-08 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
EP3019106A1 (en) | 2013-07-11 | 2016-05-18 | Boston Scientific Scimed, Inc. | Medical device with stretchable electrode assemblies |
WO2015006480A1 (en) | 2013-07-11 | 2015-01-15 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation |
WO2015010074A1 (en) | 2013-07-19 | 2015-01-22 | Boston Scientific Scimed, Inc. | Spiral bipolar electrode renal denervation balloon |
US10695124B2 (en) | 2013-07-22 | 2020-06-30 | Boston Scientific Scimed, Inc. | Renal nerve ablation catheter having twist balloon |
WO2015013205A1 (en) | 2013-07-22 | 2015-01-29 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
WO2015027096A1 (en) | 2013-08-22 | 2015-02-26 | Boston Scientific Scimed, Inc. | Flexible circuit having improved adhesion to a renal nerve modulation balloon |
EP3041425B1 (en) | 2013-09-04 | 2022-04-13 | Boston Scientific Scimed, Inc. | Radio frequency (rf) balloon catheter having flushing and cooling capability |
WO2015038947A1 (en) | 2013-09-13 | 2015-03-19 | Boston Scientific Scimed, Inc. | Ablation balloon with vapor deposited cover layer |
US11246654B2 (en) | 2013-10-14 | 2022-02-15 | Boston Scientific Scimed, Inc. | Flexible renal nerve ablation devices and related methods of use and manufacture |
CN105592778B (en) | 2013-10-14 | 2019-07-23 | 波士顿科学医学有限公司 | High-resolution cardiac mapping electrod-array conduit |
AU2014334574B2 (en) | 2013-10-15 | 2017-07-06 | Boston Scientific Scimed, Inc. | Medical device balloon |
US9770606B2 (en) | 2013-10-15 | 2017-09-26 | Boston Scientific Scimed, Inc. | Ultrasound ablation catheter with cooling infusion and centering basket |
CN105636538B (en) | 2013-10-18 | 2019-01-15 | 波士顿科学国际有限公司 | Foley's tube with flexible wire and its correlation technique for using and manufacturing |
CN105658163B (en) | 2013-10-25 | 2020-08-18 | 波士顿科学国际有限公司 | Embedded thermocouple in denervation flexible circuit |
WO2015068167A2 (en) | 2013-11-06 | 2015-05-14 | Enopace Biomedical Ltd. | Wireless endovascular stent-based electrodes |
AU2014351473B2 (en) | 2013-11-22 | 2019-11-07 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US10279184B2 (en) * | 2013-12-09 | 2019-05-07 | Ryan Kendall Pierce | Devices and methods for treating cardiovascular and metabolic disease |
WO2015103617A1 (en) | 2014-01-06 | 2015-07-09 | Boston Scientific Scimed, Inc. | Tear resistant flex circuit assembly |
EP3824949B1 (en) | 2014-01-21 | 2023-12-20 | Lungpacer Medical Inc. | Systems for optimization of multi-electrode nerve pacing |
JP6325121B2 (en) | 2014-02-04 | 2018-05-16 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Alternative placement of temperature sensors on bipolar electrodes |
US11000679B2 (en) | 2014-02-04 | 2021-05-11 | Boston Scientific Scimed, Inc. | Balloon protection and rewrapping devices and related methods of use |
EP3116408B1 (en) | 2014-03-12 | 2018-12-19 | Cibiem, Inc. | Ultrasound ablation catheter |
US11311718B2 (en) | 2014-05-16 | 2022-04-26 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
EP3476430B1 (en) | 2014-05-16 | 2020-07-01 | Aleva Neurotherapeutics SA | Device for interacting with neurological tissue |
JP6580068B2 (en) | 2014-05-22 | 2019-09-25 | カーディオノミック,インク. | Catheter and catheter system for electrical neuromodulation |
US8876850B1 (en) * | 2014-06-19 | 2014-11-04 | Aria Cv, Inc. | Systems and methods for treating pulmonary hypertension |
US20160000548A1 (en) * | 2014-07-03 | 2016-01-07 | Elwha Llc | Devices, methods, and systems related to expandable implants |
US9737716B2 (en) * | 2014-08-12 | 2017-08-22 | Cyberonics, Inc. | Vagus nerve and carotid baroreceptor stimulation system |
US9403011B2 (en) | 2014-08-27 | 2016-08-02 | Aleva Neurotherapeutics | Leadless neurostimulator |
US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
WO2016040037A1 (en) | 2014-09-08 | 2016-03-17 | CARDIONOMIC, Inc. | Catheter and electrode systems for electrical neuromodulation |
AU2015315570B2 (en) | 2014-09-08 | 2020-05-14 | CARDIONOMIC, Inc. | Methods for electrical neuromodulation of the heart |
CN109568786A (en) | 2015-01-05 | 2019-04-05 | 卡迪诺米克公司 | Heart, which is adjusted, promotes method and system |
US20180236220A1 (en) * | 2015-01-14 | 2018-08-23 | NeuroTronik IP Holding (Jersey) Limited | Inflatable intravascular electrode supports for neuromodulation |
US9974946B2 (en) * | 2015-04-07 | 2018-05-22 | NeuroTronik IP Holding (Jersey) Limited | Inflatable intravascular electrode supports for neuromodulation |
JP2018504240A (en) | 2015-02-06 | 2018-02-15 | カーディアック ペースメイカーズ, インコーポレイテッド | System and method for treating cardiac arrhythmia |
CN107864617B (en) | 2015-03-19 | 2021-08-20 | 启迪医疗仪器公司 | Stimulation for treating sleep disordered breathing |
US9855317B2 (en) * | 2015-04-27 | 2018-01-02 | Reflex Medical, Inc. | Systems and methods for sympathetic cardiopulmonary neuromodulation |
US20200254249A1 (en) | 2015-11-17 | 2020-08-13 | Inspire Medical Systems, Inc. | Microstimulation sleep disordered breathing (sdb) therapy device |
CN109069824B (en) | 2016-02-02 | 2022-09-16 | 阿莱瓦神经治疗股份有限公司 | Treatment of autoimmune diseases using deep brain stimulation |
WO2017139487A1 (en) | 2016-02-09 | 2017-08-17 | Northwind Medical, Inc. | Methods, agents, and devices for local neuromodulation of autonomic nerves |
JP2019513032A (en) | 2016-03-09 | 2019-05-23 | カーディオノミック,インク. | Cardiac contraction stimulation system and method |
EP3436140B1 (en) | 2016-04-01 | 2021-01-06 | Cyberonics, Inc. | Vagus nerve stimulation patient selection |
EP3478287A4 (en) * | 2016-06-29 | 2020-04-08 | Tulavi Therapeutics, Inc. | Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system |
US11331105B2 (en) | 2016-10-19 | 2022-05-17 | Aria Cv, Inc. | Diffusion resistant implantable devices for reducing pulsatile pressure |
FR3059557A1 (en) * | 2016-12-07 | 2018-06-08 | Universite Grenoble Alpes | IMPLANTABLE SYSTEM |
WO2018125538A1 (en) * | 2016-12-27 | 2018-07-05 | Avent, Inc. | Article for treating diabetic peripheral neuropathy |
AU2018237050B2 (en) | 2017-03-20 | 2020-03-12 | Cardiac Pacemakers, Inc. | Leadless pacing device for treating cardiac arrhythmias |
US11000690B2 (en) | 2017-03-20 | 2021-05-11 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US10994148B2 (en) | 2017-03-20 | 2021-05-04 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US11160989B2 (en) | 2017-03-20 | 2021-11-02 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
GB201707207D0 (en) * | 2017-05-05 | 2017-06-21 | Galvani Bioelectronics Ltd | Treatment of type 1 diabetes |
US10293164B2 (en) | 2017-05-26 | 2019-05-21 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
CN111163834A (en) | 2017-06-30 | 2020-05-15 | 隆佩瑟尔医疗公司 | Device for preventing, reducing and/or treating cognitive impairment |
US10709343B2 (en) | 2017-07-31 | 2020-07-14 | National Cardiac, Inc. | Computer-based systems and methods for monitoring the heart muscle of a patient with contextual oversight |
US10195429B1 (en) | 2017-08-02 | 2019-02-05 | Lungpacer Medical Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US10940308B2 (en) | 2017-08-04 | 2021-03-09 | Lungpacer Medical Inc. | Systems and methods for trans-esophageal sympathetic ganglion recruitment |
AU2018316277B2 (en) | 2017-08-11 | 2023-12-07 | Inspire Medical Systems, Inc. | Cuff electrode |
EP3664703A4 (en) | 2017-09-13 | 2021-05-12 | Cardionomic, Inc. | Neurostimulation systems and methods for affecting cardiac contractility |
NL2019909B1 (en) | 2017-11-14 | 2019-05-20 | Academisch Ziekenhuis Leiden | SYSTEM, METHOD AND CATHETER FOR PITUITARY AND BRAIN IMPLANTATION |
CN111556774A (en) | 2017-12-22 | 2020-08-18 | 心脏起搏器股份公司 | Implantable medical device for vascular deployment |
CN111491694A (en) | 2017-12-22 | 2020-08-04 | 心脏起搏器股份公司 | Implantable medical device for vascular deployment |
US10702692B2 (en) | 2018-03-02 | 2020-07-07 | Aleva Neurotherapeutics | Neurostimulation device |
AU2019299519A1 (en) | 2018-07-02 | 2021-01-28 | Incept Llc | Methods and devices for in situ formed nerve cap |
EP3836859A4 (en) | 2018-08-13 | 2022-05-11 | Cardionomic, Inc. | Systems and methods for affecting cardiac contractility and/or relaxation |
WO2020097331A1 (en) | 2018-11-08 | 2020-05-14 | Lungpacer Medical Inc. | Stimulation systems and related user interfaces |
US11806069B2 (en) * | 2019-01-25 | 2023-11-07 | Warsaw Orthopedics, IN | Devices and methods for the diagnosis and treatment of discogenic back pain |
US11446510B2 (en) | 2019-03-29 | 2022-09-20 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US11833349B2 (en) | 2019-03-29 | 2023-12-05 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
WO2020227234A1 (en) | 2019-05-06 | 2020-11-12 | CARDIONOMIC, Inc. | Systems and methods for denoising physiological signals during electrical neuromodulation |
US11093038B2 (en) | 2019-05-14 | 2021-08-17 | Synchron Australia Pty Limited | Systems and methods for generic control using a neural signal |
EP3968932A4 (en) | 2019-05-16 | 2023-01-18 | Lungpacer Medical Inc. | Systems and methods for sensing and stimulation |
US11771900B2 (en) | 2019-06-12 | 2023-10-03 | Lungpacer Medical Inc. | Circuitry for medical stimulation systems |
WO2021046252A1 (en) | 2019-09-06 | 2021-03-11 | Aria Cv, Inc. | Diffusion and infusion resistant implantable devices for reducing pulsatile pressure |
WO2021050685A1 (en) | 2019-09-11 | 2021-03-18 | Cardiac Pacemakers, Inc. | Tools and systems for implanting and/or retrieving a leadless cardiac pacing device with helix fixation |
CN114364431A (en) | 2019-09-11 | 2022-04-15 | 心脏起搏器股份公司 | Tool and system for implanting and/or retrieving a leadless cardiac pacing device having a helical fixation member |
WO2021097448A1 (en) * | 2019-11-15 | 2021-05-20 | Synchron Australia Pty Limited | Methods and devices for renal neuromodulation |
US11839767B2 (en) | 2020-01-10 | 2023-12-12 | Nuxcel2, L.L.C. | Systems and methods for stimulation of cranial nerves |
US11918802B2 (en) * | 2020-01-27 | 2024-03-05 | Medtronic, Inc. | Foramina-filling implantable medical lead |
WO2022036050A1 (en) * | 2020-08-14 | 2022-02-17 | President And Fellows Of Harvard College | Systems and methods for flexible micrometer-scale endovascular probes for neural recording |
EP4108197A1 (en) | 2021-06-24 | 2022-12-28 | Gradient Denervation Technologies | Systems for treating tissue |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020183791A1 (en) * | 2001-01-16 | 2002-12-05 | Stephen Denker | Implantable defibrillator with wireless vascular stent electrodes |
US20050149126A1 (en) * | 2003-12-24 | 2005-07-07 | Imad Libbus | Baroreflex stimulation to treat acute myocardial infarction |
US6917833B2 (en) * | 2003-09-16 | 2005-07-12 | Kenergy, Inc. | Omnidirectional antenna for wireless communication with implanted medical devices |
US6934583B2 (en) * | 2001-10-22 | 2005-08-23 | Pacesetter, Inc. | Implantable lead and method for stimulating the vagus nerve |
US20050187584A1 (en) * | 2001-01-16 | 2005-08-25 | Stephen Denker | Vagal nerve stimulation using vascular implanted devices for treatment of atrial fibrillation |
US20070106357A1 (en) * | 2005-11-04 | 2007-05-10 | Stephen Denker | Intravascular Electronics Carrier Electrode for a Transvascular Tissue Stimulation System |
US8239045B2 (en) * | 2003-06-04 | 2012-08-07 | Synecor Llc | Device and method for retaining a medical device within a vessel |
Family Cites Families (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3522811A (en) | 1969-02-13 | 1970-08-04 | Medtronic Inc | Implantable nerve stimulator and method of use |
SE346468B (en) * | 1969-02-24 | 1972-07-10 | Lkb Medical Ab | |
US3645367A (en) * | 1970-05-25 | 1972-02-29 | White Farm Equip | Operator for clutch and synchronizer brake |
US3835864A (en) | 1970-09-21 | 1974-09-17 | Rasor Ass Inc | Intra-cardiac stimulator |
US4573481A (en) * | 1984-06-25 | 1986-03-04 | Huntington Institute Of Applied Research | Implantable electrode array |
US4649936A (en) * | 1984-10-11 | 1987-03-17 | Case Western Reserve University | Asymmetric single electrode cuff for generation of unidirectionally propagating action potentials for collision blocking |
US4881939A (en) | 1985-02-19 | 1989-11-21 | The Johns Hopkins University | Implantable helical cuff |
US5458631A (en) * | 1989-01-06 | 1995-10-17 | Xavier; Ravi | Implantable catheter with electrical pulse nerve stimulators and drug delivery system |
US5154172A (en) | 1989-11-13 | 1992-10-13 | Cyberonics, Inc. | Constant current sources with programmable voltage source |
US5179950A (en) * | 1989-11-13 | 1993-01-19 | Cyberonics, Inc. | Implanted apparatus having micro processor controlled current and voltage sources with reduced voltage levels when not providing stimulation |
US5224491A (en) * | 1991-01-07 | 1993-07-06 | Medtronic, Inc. | Implantable electrode for location within a blood vessel |
US5170802A (en) | 1991-01-07 | 1992-12-15 | Medtronic, Inc. | Implantable electrode for location within a blood vessel |
US5269303A (en) | 1991-02-22 | 1993-12-14 | Cyberonics, Inc. | Treatment of dementia by nerve stimulation |
US5199428A (en) * | 1991-03-22 | 1993-04-06 | Medtronic, Inc. | Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload |
US5318592A (en) * | 1991-09-12 | 1994-06-07 | BIOTRONIK, Mess- und Therapiegerate GmbH & Co., Ingenieurburo Berlin | Cardiac therapy system |
US5304206A (en) * | 1991-11-18 | 1994-04-19 | Cyberonics, Inc. | Activation techniques for implantable medical device |
US5203326A (en) * | 1991-12-18 | 1993-04-20 | Telectronics Pacing Systems, Inc. | Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy |
US5330507A (en) * | 1992-04-24 | 1994-07-19 | Medtronic, Inc. | Implantable electrical vagal stimulation for prevention or interruption of life threatening arrhythmias |
DE69315704T3 (en) * | 1992-10-01 | 2002-08-01 | Cardiac Pacemakers Inc | STENT-LIKE STRUCTURE FOR DEFLICTION ELECTRODES |
US5607463A (en) * | 1993-03-30 | 1997-03-04 | Medtronic, Inc. | Intravascular medical device |
US5487760A (en) * | 1994-03-08 | 1996-01-30 | Ats Medical, Inc. | Heart valve prosthesis incorporating electronic sensing, monitoring and/or pacing circuitry |
US5540734A (en) * | 1994-09-28 | 1996-07-30 | Zabara; Jacob | Cranial nerve stimulation treatments using neurocybernetic prosthesis |
US5707400A (en) * | 1995-09-19 | 1998-01-13 | Cyberonics, Inc. | Treating refractory hypertension by nerve stimulation |
US5755750A (en) * | 1995-11-13 | 1998-05-26 | University Of Florida | Method and apparatus for selectively inhibiting activity in nerve fibers |
US6073048A (en) * | 1995-11-17 | 2000-06-06 | Medtronic, Inc. | Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure |
US5651378A (en) * | 1996-02-20 | 1997-07-29 | Cardiothoracic Systems, Inc. | Method of using vagal nerve stimulation in surgery |
US5913876A (en) * | 1996-02-20 | 1999-06-22 | Cardiothoracic Systems, Inc. | Method and apparatus for using vagus nerve stimulation in surgery |
US5690681A (en) | 1996-03-29 | 1997-11-25 | Purdue Research Foundation | Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation |
USRE38705E1 (en) | 1996-04-30 | 2005-02-22 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
US6006134A (en) * | 1998-04-30 | 1999-12-21 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
US6449507B1 (en) | 1996-04-30 | 2002-09-10 | Medtronic, Inc. | Method and system for nerve stimulation prior to and during a medical procedure |
US7225019B2 (en) | 1996-04-30 | 2007-05-29 | Medtronic, Inc. | Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure |
US7269457B2 (en) | 1996-04-30 | 2007-09-11 | Medtronic, Inc. | Method and system for vagal nerve stimulation with multi-site cardiac pacing |
US6104956A (en) | 1996-05-31 | 2000-08-15 | Board Of Trustees Of Southern Illinois University | Methods of treating traumatic brain injury by vagus nerve stimulation |
US6231516B1 (en) * | 1997-10-14 | 2001-05-15 | Vacusense, Inc. | Endoluminal implant with therapeutic and diagnostic capability |
US6415187B1 (en) * | 1998-02-10 | 2002-07-02 | Advanced Bionics Corporation | Implantable, expandable, multicontact electrodes and insertion needle for use therewith |
US6161047A (en) * | 1998-04-30 | 2000-12-12 | Medtronic Inc. | Apparatus and method for expanding a stimulation lead body in situ |
US6319241B1 (en) | 1998-04-30 | 2001-11-20 | Medtronic, Inc. | Techniques for positioning therapy delivery elements within a spinal cord or a brain |
US5928272A (en) * | 1998-05-02 | 1999-07-27 | Cyberonics, Inc. | Automatic activation of a neurostimulator device using a detection algorithm based on cardiac activity |
CA2331532A1 (en) * | 1998-05-08 | 1999-11-18 | Genetronics, Inc. | Electrically induced vessel vasodilation |
WO1999065561A1 (en) | 1998-06-19 | 1999-12-23 | Cordis Webster, Inc. | Method and apparatus for transvascular treatment of tachycardia and fibrillation |
US6141588A (en) | 1998-07-24 | 2000-10-31 | Intermedics Inc. | Cardiac simulation system having multiple stimulators for anti-arrhythmia therapy |
US7076307B2 (en) | 2002-05-09 | 2006-07-11 | Boveja Birinder R | Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders |
US6393325B1 (en) * | 1999-01-07 | 2002-05-21 | Advanced Bionics Corporation | Directional programming for implantable electrode arrays |
US6178349B1 (en) * | 1999-04-15 | 2001-01-23 | Medtronic, Inc. | Drug delivery neural stimulation device for treatment of cardiovascular disorders |
US6341236B1 (en) | 1999-04-30 | 2002-01-22 | Ivan Osorio | Vagal nerve stimulation techniques for treatment of epileptic seizures |
US7092753B2 (en) * | 1999-06-04 | 2006-08-15 | Impulse Dynamics Nv | Drug delivery device |
US6587719B1 (en) | 1999-07-01 | 2003-07-01 | Cyberonics, Inc. | Treatment of obesity by bilateral vagus nerve stimulation |
US6473644B1 (en) | 1999-10-13 | 2002-10-29 | Cyberonics, Inc. | Method to enhance cardiac capillary growth in heart failure patients |
US7300449B2 (en) | 1999-12-09 | 2007-11-27 | Mische Hans A | Methods and devices for the treatment of neurological and physiological disorders |
US6764498B2 (en) * | 1999-12-09 | 2004-07-20 | Hans Alois Mische | Methods and devices for treatment of neurological disorders |
US6375666B1 (en) * | 1999-12-09 | 2002-04-23 | Hans Alois Mische | Methods and devices for treatment of neurological disorders |
EP1106202A3 (en) * | 1999-11-30 | 2004-03-31 | BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin | Electrode for intravascular stimulation, cardioversion and /or defibrillation |
US6442413B1 (en) | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
US6522926B1 (en) * | 2000-09-27 | 2003-02-18 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control |
US6850801B2 (en) | 2001-09-26 | 2005-02-01 | Cvrx, Inc. | Mapping methods for cardiovascular reflex control devices |
US7623926B2 (en) | 2000-09-27 | 2009-11-24 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US7158832B2 (en) * | 2000-09-27 | 2007-01-02 | Cvrx, Inc. | Electrode designs and methods of use for cardiovascular reflex control devices |
US7616997B2 (en) | 2000-09-27 | 2009-11-10 | Kieval Robert S | Devices and methods for cardiovascular reflex control via coupled electrodes |
US7499742B2 (en) * | 2001-09-26 | 2009-03-03 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US6985774B2 (en) * | 2000-09-27 | 2006-01-10 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US8086314B1 (en) * | 2000-09-27 | 2011-12-27 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control |
US6845267B2 (en) * | 2000-09-28 | 2005-01-18 | Advanced Bionics Corporation | Systems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation |
AU2002210378A1 (en) * | 2000-10-11 | 2002-04-22 | Ronald R. Riso | Nerve cuff electrode |
US6616624B1 (en) | 2000-10-30 | 2003-09-09 | Cvrx, Inc. | Systems and method for controlling renovascular perfusion |
US6681136B2 (en) * | 2000-12-04 | 2004-01-20 | Science Medicus, Inc. | Device and method to modulate blood pressure by electrical waveforms |
US6600954B2 (en) * | 2001-01-25 | 2003-07-29 | Biocontrol Medical Bcm Ltd. | Method and apparatus for selective control of nerve fibers |
US7167751B1 (en) * | 2001-03-01 | 2007-01-23 | Advanced Bionics Corporation | Method of using a fully implantable miniature neurostimulator for vagus nerve stimulation |
US6684105B2 (en) * | 2001-08-31 | 2004-01-27 | Biocontrol Medical, Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US6907295B2 (en) * | 2001-08-31 | 2005-06-14 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
US6622041B2 (en) | 2001-08-21 | 2003-09-16 | Cyberonics, Inc. | Treatment of congestive heart failure and autonomic cardiovascular drive disorders |
US7734355B2 (en) | 2001-08-31 | 2010-06-08 | Bio Control Medical (B.C.M.) Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US7778711B2 (en) | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Reduction of heart rate variability by parasympathetic stimulation |
US7155284B1 (en) | 2002-01-24 | 2006-12-26 | Advanced Bionics Corporation | Treatment of hypertension |
US6721603B2 (en) * | 2002-01-25 | 2004-04-13 | Cyberonics, Inc. | Nerve stimulation as a treatment for pain |
US7236821B2 (en) * | 2002-02-19 | 2007-06-26 | Cardiac Pacemakers, Inc. | Chronically-implanted device for sensing and therapy |
AU2003212640A1 (en) * | 2002-03-14 | 2003-09-22 | Brainsgate Ltd. | Technique for blood pressure regulation |
US7162303B2 (en) * | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US20070135875A1 (en) * | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US8347891B2 (en) * | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US8175711B2 (en) | 2002-04-08 | 2012-05-08 | Ardian, Inc. | Methods for treating a condition or disease associated with cardio-renal function |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US8774913B2 (en) * | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US8145316B2 (en) * | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US20050216070A1 (en) | 2002-05-09 | 2005-09-29 | Boveja Birinder R | Method and system for providing therapy for migraine/chronic headache by providing electrical pulses to vagus nerve(s) |
US7191012B2 (en) | 2003-05-11 | 2007-03-13 | Boveja Birinder R | Method and system for providing pulsed electrical stimulation to a craniel nerve of a patient to provide therapy for neurological and neuropsychiatric disorders |
US20060009815A1 (en) * | 2002-05-09 | 2006-01-12 | Boveja Birinder R | Method and system to provide therapy or alleviate symptoms of involuntary movement disorders by providing complex and/or rectangular electrical pulses to vagus nerve(s) |
US7321793B2 (en) * | 2003-06-13 | 2008-01-22 | Biocontrol Medical Ltd. | Vagal stimulation for atrial fibrillation therapy |
US7277761B2 (en) | 2002-06-12 | 2007-10-02 | Pacesetter, Inc. | Vagal stimulation for improving cardiac function in heart failure or CHF patients |
US7203548B2 (en) * | 2002-06-20 | 2007-04-10 | Advanced Bionics Corporation | Cavernous nerve stimulation via unidirectional propagation of action potentials |
US7292890B2 (en) | 2002-06-20 | 2007-11-06 | Advanced Bionics Corporation | Vagus nerve stimulation via unidirectional propagation of action potentials |
SE0202537D0 (en) | 2002-08-28 | 2002-08-28 | Siemens Elema Ab | Nerve stimulation apparatus |
US20030229380A1 (en) | 2002-10-31 | 2003-12-11 | Adams John M. | Heart failure therapy device and method |
US20040106954A1 (en) | 2002-11-15 | 2004-06-03 | Whitehurst Todd K. | Treatment of congestive heart failure |
US7305265B2 (en) | 2002-11-25 | 2007-12-04 | Terumo Kabushiki Kaisha | Heart treatment equipment for treating heart failure |
US8064994B2 (en) | 2003-01-14 | 2011-11-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Cervical vagal stimulation induced weight loss |
US7167750B2 (en) | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
JP2006517849A (en) | 2003-02-18 | 2006-08-03 | サイエンス・メディカス・インコーポレイテッド | Implantable method of controlling blood pressure with coded neural signals |
JP4252830B2 (en) * | 2003-03-24 | 2009-04-08 | テルモ株式会社 | Heart treatment equipment |
US7155279B2 (en) | 2003-03-28 | 2006-12-26 | Advanced Bionics Corporation | Treatment of movement disorders with drug therapy |
US7082336B2 (en) | 2003-06-04 | 2006-07-25 | Synecor, Llc | Implantable intravascular device for defibrillation and/or pacing |
JP4616252B2 (en) * | 2003-06-04 | 2011-01-19 | シネコー・エルエルシー | Intravascular electrophysiology system and method |
US7617007B2 (en) | 2003-06-04 | 2009-11-10 | Synecor Llc | Method and apparatus for retaining medical implants within body vessels |
US7149574B2 (en) | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
US7263405B2 (en) * | 2003-08-27 | 2007-08-28 | Neuro And Cardiac Technologies Llc | System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities |
US20050070974A1 (en) * | 2003-09-29 | 2005-03-31 | Knudson Mark B. | Obesity and eating disorder stimulation treatment with neural block |
US20050131467A1 (en) * | 2003-11-02 | 2005-06-16 | Boveja Birinder R. | Method and apparatus for electrical stimulation therapy for at least one of atrial fibrillation, congestive heart failure, inappropriate sinus tachycardia, and refractory hypertension |
WO2005058415A2 (en) * | 2003-12-12 | 2005-06-30 | Synecor, Llc | Implantable medical device having pre-implant exoskeleton |
US20050137646A1 (en) * | 2003-12-22 | 2005-06-23 | Scimed Life Systems, Inc. | Method of intravascularly delivering stimulation leads into brain |
US8126560B2 (en) * | 2003-12-24 | 2012-02-28 | Cardiac Pacemakers, Inc. | Stimulation lead for stimulating the baroreceptors in the pulmonary artery |
US7486991B2 (en) * | 2003-12-24 | 2009-02-03 | Cardiac Pacemakers, Inc. | Baroreflex modulation to gradually decrease blood pressure |
US8396560B2 (en) * | 2004-11-18 | 2013-03-12 | Cardiac Pacemakers, Inc. | System and method for closed-loop neural stimulation |
US20050149133A1 (en) * | 2003-12-24 | 2005-07-07 | Imad Libbus | Sensing with compensation for neural stimulator |
US20050149129A1 (en) * | 2003-12-24 | 2005-07-07 | Imad Libbus | Baropacing and cardiac pacing to control output |
US7643875B2 (en) * | 2003-12-24 | 2010-01-05 | Cardiac Pacemakers, Inc. | Baroreflex stimulation system to reduce hypertension |
US7706884B2 (en) * | 2003-12-24 | 2010-04-27 | Cardiac Pacemakers, Inc. | Baroreflex stimulation synchronized to circadian rhythm |
US7647114B2 (en) * | 2003-12-24 | 2010-01-12 | Cardiac Pacemakers, Inc. | Baroreflex modulation based on monitored cardiovascular parameter |
US8024050B2 (en) * | 2003-12-24 | 2011-09-20 | Cardiac Pacemakers, Inc. | Lead for stimulating the baroreceptors in the pulmonary artery |
US7509166B2 (en) * | 2003-12-24 | 2009-03-24 | Cardiac Pacemakers, Inc. | Automatic baroreflex modulation responsive to adverse event |
US20050149132A1 (en) * | 2003-12-24 | 2005-07-07 | Imad Libbus | Automatic baroreflex modulation based on cardiac activity |
US7869881B2 (en) * | 2003-12-24 | 2011-01-11 | Cardiac Pacemakers, Inc. | Baroreflex stimulator with integrated pressure sensor |
US7295881B2 (en) | 2003-12-29 | 2007-11-13 | Biocontrol Medical Ltd. | Nerve-branch-specific action-potential activation, inhibition, and monitoring |
WO2005077450A2 (en) | 2004-02-10 | 2005-08-25 | Synecor, Llc | Intravascular delivery system for therapeutic agents |
US7295875B2 (en) | 2004-02-20 | 2007-11-13 | Boston Scientific Scimed, Inc. | Method of stimulating/sensing brain with combination of intravascularly and non-vascularly delivered leads |
US7177702B2 (en) * | 2004-03-12 | 2007-02-13 | Scimed Life Systems, Inc. | Collapsible/expandable electrode leads |
US20050203600A1 (en) | 2004-03-12 | 2005-09-15 | Scimed Life Systems, Inc. | Collapsible/expandable tubular electrode leads |
US7590454B2 (en) | 2004-03-12 | 2009-09-15 | Boston Scientific Neuromodulation Corporation | Modular stimulation lead network |
US8412348B2 (en) | 2004-05-06 | 2013-04-02 | Boston Scientific Neuromodulation Corporation | Intravascular self-anchoring integrated tubular electrode body |
WO2006012050A2 (en) * | 2004-06-30 | 2006-02-02 | Cvrx, Inc. | Connection structures for extra-vascular electrode lead body |
US7286879B2 (en) * | 2004-07-16 | 2007-10-23 | Boston Scientific Scimed, Inc. | Method of stimulating fastigium nucleus to treat neurological disorders |
US7373204B2 (en) * | 2004-08-19 | 2008-05-13 | Lifestim, Inc. | Implantable device and method for treatment of hypertension |
US20060058854A1 (en) * | 2004-09-14 | 2006-03-16 | Scimed Life Systems, Inc. | Method for stimulating neural tissue in response to a sensed physiological event |
US20060074453A1 (en) * | 2004-10-04 | 2006-04-06 | Cvrx, Inc. | Baroreflex activation and cardiac resychronization for heart failure treatment |
US7937143B2 (en) * | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
US20070083239A1 (en) * | 2005-09-23 | 2007-04-12 | Denise Demarais | Methods and apparatus for inducing, monitoring and controlling renal neuromodulation |
US10537741B2 (en) | 2004-12-03 | 2020-01-21 | Boston Scientific Neuromodulation Corporation | System and method for choosing electrodes in an implanted stimulator device |
US7366571B2 (en) * | 2004-12-10 | 2008-04-29 | Cyberonics, Inc. | Neurostimulator with activation based on changes in body temperature |
US7363082B2 (en) * | 2005-03-24 | 2008-04-22 | Synecor Llc | Flexible hermetic enclosure for implantable medical devices |
US7499748B2 (en) | 2005-04-11 | 2009-03-03 | Cardiac Pacemakers, Inc. | Transvascular neural stimulation device |
US7310557B2 (en) | 2005-04-29 | 2007-12-18 | Maschino Steven E | Identification of electrodes for nerve stimulation in the treatment of eating disorders |
US7561923B2 (en) | 2005-05-09 | 2009-07-14 | Cardiac Pacemakers, Inc. | Method and apparatus for controlling autonomic balance using neural stimulation |
US7734348B2 (en) | 2005-05-10 | 2010-06-08 | Cardiac Pacemakers, Inc. | System with left/right pulmonary artery electrodes |
US7765000B2 (en) | 2005-05-10 | 2010-07-27 | Cardiac Pacemakers, Inc. | Neural stimulation system with pulmonary artery lead |
US7395119B2 (en) | 2005-05-19 | 2008-07-01 | Cvrx, Inc. | Implantable electrode assembly having reverse electrode configuration |
US8862243B2 (en) | 2005-07-25 | 2014-10-14 | Rainbow Medical Ltd. | Electrical stimulation of blood vessels |
US7856273B2 (en) * | 2005-07-28 | 2010-12-21 | Cyberonics, Inc. | Autonomic nerve stimulation to treat a gastrointestinal disorder |
US7532935B2 (en) * | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
US20070043414A1 (en) * | 2005-08-15 | 2007-02-22 | Fifer Daniel W | Lead fixation and extraction |
US9026215B2 (en) | 2005-12-29 | 2015-05-05 | Cvrx, Inc. | Hypertension treatment device and method for mitigating rapid changes in blood pressure |
US20080004673A1 (en) * | 2006-04-03 | 2008-01-03 | Cvrx, Inc. | Implantable extravascular electrostimulation system having a resilient cuff |
CA2676119C (en) * | 2007-01-29 | 2021-01-19 | Simon Fraser University | Transvascular nerve stimulation apparatus and methods |
-
2007
- 2007-02-02 EP EP07763673.6A patent/EP1981584B1/en not_active Not-in-force
- 2007-02-02 WO PCT/US2007/002932 patent/WO2007092330A1/en active Application Filing
- 2007-02-02 AU AU2007212587A patent/AU2007212587B2/en not_active Ceased
- 2007-02-02 JP JP2008553377A patent/JP5256048B2/en not_active Expired - Fee Related
- 2007-02-02 US US11/702,000 patent/US8116883B2/en not_active Expired - Fee Related
- 2007-02-02 CA CA002637787A patent/CA2637787A1/en not_active Abandoned
-
2011
- 2011-11-10 US US13/294,140 patent/US20120059431A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020183791A1 (en) * | 2001-01-16 | 2002-12-05 | Stephen Denker | Implantable defibrillator with wireless vascular stent electrodes |
US20050187584A1 (en) * | 2001-01-16 | 2005-08-25 | Stephen Denker | Vagal nerve stimulation using vascular implanted devices for treatment of atrial fibrillation |
US6934583B2 (en) * | 2001-10-22 | 2005-08-23 | Pacesetter, Inc. | Implantable lead and method for stimulating the vagus nerve |
US8239045B2 (en) * | 2003-06-04 | 2012-08-07 | Synecor Llc | Device and method for retaining a medical device within a vessel |
US6917833B2 (en) * | 2003-09-16 | 2005-07-12 | Kenergy, Inc. | Omnidirectional antenna for wireless communication with implanted medical devices |
US20050149126A1 (en) * | 2003-12-24 | 2005-07-07 | Imad Libbus | Baroreflex stimulation to treat acute myocardial infarction |
US20070106357A1 (en) * | 2005-11-04 | 2007-05-10 | Stephen Denker | Intravascular Electronics Carrier Electrode for a Transvascular Tissue Stimulation System |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8538533B2 (en) | 2003-02-03 | 2013-09-17 | Enteromedics Inc. | Controlled vagal blockage therapy |
US9174040B2 (en) | 2003-02-03 | 2015-11-03 | Enteromedics Inc. | Nerve stimulation and blocking for treatment of gastrointestinal disorders |
US8862233B2 (en) | 2003-02-03 | 2014-10-14 | Enteromedics Inc. | Electrode band system and methods of using the system to treat obesity |
US9162062B2 (en) | 2003-02-03 | 2015-10-20 | Enteromedics Inc. | Controlled vagal blockage therapy |
US9586046B2 (en) | 2003-02-03 | 2017-03-07 | Enteromedics, Inc. | Electrode band system and methods of using the system to treat obesity |
US9682233B2 (en) | 2003-02-03 | 2017-06-20 | Enteromedics Inc. | Nerve stimulation and blocking for treatment of gastrointestinal disorders |
US8538542B2 (en) | 2003-02-03 | 2013-09-17 | Enteromedics Inc. | Nerve stimulation and blocking for treatment of gastrointestinal disorders |
US20110118632A1 (en) * | 2003-02-20 | 2011-05-19 | Recor Medical, Inc. | Cardiac ablation devices |
US10499937B2 (en) | 2006-05-19 | 2019-12-10 | Recor Medical, Inc. | Ablation device with optimized input power profile and method of using the same |
US20100130892A1 (en) * | 2006-05-19 | 2010-05-27 | Prorhythm, In. | Ablation device with optimized input power profile and method of using the same |
US8521299B2 (en) | 2007-03-09 | 2013-08-27 | Enteromedics Inc. | Remote monitoring and control of implantable devices |
US20080281365A1 (en) * | 2007-05-09 | 2008-11-13 | Tweden Katherine S | Neural signal duty cycle |
US8532787B2 (en) | 2007-05-31 | 2013-09-10 | Enteromedics Inc. | Implantable therapy system having multiple operating modes |
US9186502B2 (en) | 2008-02-14 | 2015-11-17 | Enteromedics Inc. | Treatment of excess weight by neural downregulation in combination with compositions |
US20090210019A1 (en) * | 2008-02-14 | 2009-08-20 | Dennis Dong-Won Kim | Treatment of excess weight by neural downregulation in combination with compositions |
US9333340B2 (en) | 2008-04-04 | 2016-05-10 | Enteromedics Inc. | Methods and systems for glucose regulation |
US10722714B2 (en) | 2008-04-04 | 2020-07-28 | Reshape Lifesciences, Inc. | Methods and systems for glucose regulation |
US9974955B2 (en) | 2008-04-04 | 2018-05-22 | Reshape Lifesciences Inc. | Methods and systems for glucose regulation |
US9616231B2 (en) | 2008-08-08 | 2017-04-11 | Enteromedics Inc. | Systems for regulation of blood pressure and heart rate |
US8768469B2 (en) | 2008-08-08 | 2014-07-01 | Enteromedics Inc. | Systems for regulation of blood pressure and heart rate |
US9095711B2 (en) | 2008-08-08 | 2015-08-04 | Enteromedics Inc. | Systems for regulation of blood pressure and heart rate |
US8974445B2 (en) | 2009-01-09 | 2015-03-10 | Recor Medical, Inc. | Methods and apparatus for treatment of cardiac valve insufficiency |
US8594806B2 (en) | 2010-04-30 | 2013-11-26 | Cyberonics, Inc. | Recharging and communication lead for an implantable device |
US9358395B2 (en) | 2010-06-11 | 2016-06-07 | Enteromedics Inc. | Neural modulation devices and methods |
US9968778B2 (en) | 2010-06-11 | 2018-05-15 | Reshape Lifesciences Inc. | Neural modulation devices and methods |
US8825164B2 (en) | 2010-06-11 | 2014-09-02 | Enteromedics Inc. | Neural modulation devices and methods |
US11351050B2 (en) | 2010-06-13 | 2022-06-07 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US11607329B2 (en) | 2010-06-13 | 2023-03-21 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10413436B2 (en) | 2010-06-13 | 2019-09-17 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10512557B2 (en) | 2010-06-13 | 2019-12-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US11135078B2 (en) | 2010-06-13 | 2021-10-05 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US11596538B2 (en) | 2010-06-13 | 2023-03-07 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US9393420B2 (en) | 2012-03-09 | 2016-07-19 | Enteromedics Inc. | Safety features for use in medical devices |
US9233247B2 (en) * | 2013-03-15 | 2016-01-12 | Boston Scientific Neuromodulation Corporation | Neuromodulation of renal nerve for treatment of hypertension |
US20140277253A1 (en) * | 2013-03-15 | 2014-09-18 | Boston Scientific Neuromodulation Corporation | Neuromodulation of renal nerve for treatment of hypertension |
US10674928B2 (en) | 2014-07-17 | 2020-06-09 | Medtronic, Inc. | Leadless pacing system including sensing extension |
US10390720B2 (en) | 2014-07-17 | 2019-08-27 | Medtronic, Inc. | Leadless pacing system including sensing extension |
USRE48197E1 (en) | 2014-07-25 | 2020-09-08 | Medtronic, Inc. | Atrial contraction detection by a ventricular leadless pacing device for atrio-synchronous ventricular pacing |
US9399140B2 (en) | 2014-07-25 | 2016-07-26 | Medtronic, Inc. | Atrial contraction detection by a ventricular leadless pacing device for atrio-synchronous ventricular pacing |
US9492668B2 (en) | 2014-11-11 | 2016-11-15 | Medtronic, Inc. | Mode switching by a ventricular leadless pacing device |
US9808628B2 (en) | 2014-11-11 | 2017-11-07 | Medtronic, Inc. | Mode switching by a ventricular leadless pacing device |
US9724519B2 (en) | 2014-11-11 | 2017-08-08 | Medtronic, Inc. | Ventricular leadless pacing device mode switching |
US9623234B2 (en) | 2014-11-11 | 2017-04-18 | Medtronic, Inc. | Leadless pacing device implantation |
US10279168B2 (en) | 2014-11-11 | 2019-05-07 | Medtronic, Inc. | Leadless pacing device implantation |
US9492669B2 (en) | 2014-11-11 | 2016-11-15 | Medtronic, Inc. | Mode switching by a ventricular leadless pacing device |
US9289612B1 (en) | 2014-12-11 | 2016-03-22 | Medtronic Inc. | Coordination of ventricular pacing in a leadless pacing system |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US11207527B2 (en) | 2016-07-06 | 2021-12-28 | Cardiac Pacemakers, Inc. | Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
EP3905993A4 (en) * | 2019-01-02 | 2022-10-12 | Shifamed Holdings, LLC | Multi-transmitter sensor system |
US11801369B2 (en) | 2020-08-25 | 2023-10-31 | Shifamed Holdings, Llc | Adjustable interatrial shunts and associated systems and methods |
US11633194B2 (en) | 2020-11-12 | 2023-04-25 | Shifamed Holdings, Llc | Adjustable implantable devices and associated methods |
US11857197B2 (en) | 2020-11-12 | 2024-01-02 | Shifamed Holdings, Llc | Adjustable implantable devices and associated methods |
Also Published As
Publication number | Publication date |
---|---|
JP5256048B2 (en) | 2013-08-07 |
AU2007212587A1 (en) | 2007-08-16 |
AU2007212587B2 (en) | 2012-07-12 |
US20070255379A1 (en) | 2007-11-01 |
JP2009538634A (en) | 2009-11-12 |
CA2637787A1 (en) | 2007-08-16 |
EP1981584B1 (en) | 2015-05-13 |
WO2007092330A1 (en) | 2007-08-16 |
US8116883B2 (en) | 2012-02-14 |
EP1981584A1 (en) | 2008-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8116883B2 (en) | Intravascular device for neuromodulation | |
US8126561B2 (en) | Implantable and rechargeable neural stimulator | |
US9031669B2 (en) | System for transvascularly stimulating autonomic targets | |
US8473076B2 (en) | Lead for stimulating the baroreceptors in the pulmonary artery | |
US8725247B2 (en) | Unidirectional neural stimulation systems, devices and methods | |
JP4633737B2 (en) | Device for stimulating baroreceptors in pulmonary arteries | |
AU2011250875B2 (en) | Unidirectional neural stimulation systems, devices and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INTERVENTIONAL AUTONOMICS CORPORATION, NORTH CAROL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SYNECOR LLC;REEL/FRAME:033743/0614 Effective date: 20131217 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |